FI108797B - Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja - Google Patents

Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja Download PDF

Info

Publication number: FI108797B
Authority: FI; Finland
Prior art keywords: immunoglobulin; human; antibody; humanized; donor
Prior art date: 1988-12-28

Application number

FI912436A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI912436A0 (fi

Inventor

Cary L Queen

Harold Edwin Selick

Original Assignee

Protein Design Labs Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-28

Filing date

1991-05-20

Publication date

2002-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI108797(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-05-20 Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc

1991-05-20 Publication of FI912436A0 publication Critical patent/FI912436A0/fi

2002-03-28 Application granted granted Critical

2002-03-28 Publication of FI108797B publication Critical patent/FI108797B/fi

Links

108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 133
102000018358 immunoglobulin Human genes 0.000 title claims abstract description 133
238000000034 method Methods 0.000 title claims description 40
108091033319 polynucleotide Proteins 0.000 title claims description 9
239000002157 polynucleotide Substances 0.000 title claims description 9
102000040430 polynucleotide Human genes 0.000 title claims description 9
229940072221 immunoglobulins Drugs 0.000 title description 32
150000001413 amino acids Chemical class 0.000 claims abstract description 84
230000027455 binding Effects 0.000 claims abstract description 31
102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 27
108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract description 17
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 15
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 15
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 15
102000005962 receptors Human genes 0.000 claims abstract description 10
108020003175 receptors Proteins 0.000 claims abstract description 10
102000055277 human IL2 Human genes 0.000 claims abstract 2
210000004027 cell Anatomy 0.000 claims description 76
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 51
210000001744 T-lymphocyte Anatomy 0.000 claims description 22
239000000427 antigen Substances 0.000 claims description 22
108091007433 antigens Proteins 0.000 claims description 22
102000036639 antigens Human genes 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 16
125000003275 alpha amino acid group Chemical group 0.000 claims description 11
230000001225 therapeutic effect Effects 0.000 claims description 10
230000008569 process Effects 0.000 claims description 4
230000000903 blocking effect Effects 0.000 claims description 3
238000000746 purification Methods 0.000 claims description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 56
102000004169 proteins and genes Human genes 0.000 abstract description 28
241001529936 Murinae Species 0.000 abstract description 12
150000007523 nucleic acids Chemical class 0.000 abstract description 3
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 description 26
239000000203 mixture Substances 0.000 description 20
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
239000013612 plasmid Substances 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
201000010099 disease Diseases 0.000 description 14
239000012634 fragment Substances 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
238000009472 formulation Methods 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
238000011282 treatment Methods 0.000 description 9
239000013598 vector Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
239000002596 immunotoxin Substances 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
229940127089 cytotoxic agent Drugs 0.000 description 7
230000002637 immunotoxin Effects 0.000 description 7
229940051026 immunotoxin Drugs 0.000 description 7
231100000608 immunotoxin Toxicity 0.000 description 7
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
239000002254 cytotoxic agent Substances 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
230000006870 function Effects 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
108090001008 Avidin Proteins 0.000 description 4
241000283707 Capra Species 0.000 description 4
108010004729 Phycoerythrin Proteins 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
108010039491 Ricin Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000011651 chromium Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
206010003445 Ascites Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000013461 design Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000012546 transfer Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000157426 Pernis Species 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241001474728 Satyrodes eurydice Species 0.000 description 1
241000607720 Serratia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
-1 etc. Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940002004 the magic bullet Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FI912436A 1988-12-28 1991-05-20 Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja FI108797B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US29097588A	1988-12-28	1988-12-28
US29097588		1988-12-28
US31025289A	1989-02-13	1989-02-13
US31025289		1989-02-13
US8905857		1989-12-28
PCT/US1989/005857 WO1990007861A1 (en)	1988-12-28	1989-12-28	CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Publications (2)

Publication Number	Publication Date
FI912436A0 FI912436A0 (fi)	1991-05-20
FI108797B true FI108797B (fi)	2002-03-28

Family

ID=26966505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI912436A FI108797B (fi)	1988-12-28	1991-05-20	Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja

Country Status (32)

Country	Link
EP (6)	EP1491556B1 (da)
JP (6)	JP2828340B2 (da)
KR (1)	KR0178385B1 (da)
CN (1)	CN1057013C (da)
AT (2)	ATE133452T1 (da)
AU (1)	AU647383B2 (da)
BG (1)	BG61095B2 (da)
CA (2)	CA2006865C (da)
CZ (1)	CZ418691A3 (da)
DD (1)	DD296964A5 (da)
DE (14)	DE04076439T1 (da)
DK (2)	DK119191D0 (da)
ES (5)	ES2136760T3 (da)
FI (1)	FI108797B (da)
FR (1)	FR14C0070I1 (da)
HK (1)	HK1014718A1 (da)
HR (1)	HRP920500B1 (da)
HU (1)	HU211174A9 (da)
IE (1)	IE20000331A1 (da)
IL (2)	IL162181A (da)
LU (8)	LU90411I2 (da)
MC (1)	MC2146A1 (da)
NL (8)	NL990020I2 (da)
NO (9)	NO310473B1 (da)
NZ (2)	NZ231984A (da)
PT (1)	PT92758B (da)
RU (1)	RU2126046C1 (da)
SG (1)	SG78258A1 (da)
SI (1)	SI8912489B (da)
WO (1)	WO1990007861A1 (da)
YU (1)	YU48700B (da)
ZA (1)	ZA899956B (da)

Families Citing this family (971)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800815A (en) *	1903-05-05	1998-09-01	Cytel Corporation	Antibodies to P-selectin and their uses
US5851526A (en) *	1985-04-19	1998-12-22	Ludwig Institute For Cancer Research	Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) *	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7247453B1 (en) *	1988-12-30	2007-07-24	Oklahoma Medical Research Foundation	Calcium binding recombinant antibody against protein C
DE3900534A1 (de) *	1989-01-10	1990-07-12	Boehringer Mannheim Gmbh	Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GR1001050B (el) *	1990-01-09	1993-04-28	Protein Design Labs Inc	Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en)	1990-03-16	1992-10-28	Sandoz Ag	Process for producing cd25 fixing molecules
GB9020282D0 (en)	1990-09-17	1990-10-31	Gorman Scott D	Altered antibodies and their preparation
US5858725A (en) *	1990-10-10	1999-01-12	Glaxo Wellcome Inc.	Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) *	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
CA2082160C (en) *	1991-03-06	2003-05-06	Mary M. Bendig	Humanised and chimeric monoclonal antibodies
IE920716A1 (en) *	1991-03-07	1992-09-09	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
WO1992017505A1 (en) *	1991-04-05	1992-10-15	Board Of Regents Of The University Of Washington	Monoclonal antibodies to stem cell factor receptors
ES2134212T3 (es) *	1991-04-25	1999-10-01	Chugai Pharmaceutical Co Ltd	Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
EP0519596B1 (en) *	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
DK0590058T3 (da) *	1991-06-14	2004-03-29	Genentech Inc	Humaniseret heregulin-antistof
GB9115010D0 (en) *	1991-07-11	1991-08-28	Wellcome Found	Antibody
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
HU220295B (hu) *	1991-07-25	2001-11-28	Idec Pharmaceuticals Corp.	Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására
US5756096A (en) *	1991-07-25	1998-05-26	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US6136310A (en) *	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
US5709860A (en) *	1991-07-25	1998-01-20	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
US6699472B2 (en)	1991-08-14	2004-03-02	Genentech, Inc.	Method of treating allergic disorders
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
DE69230545T2 (de) *	1991-08-21	2000-07-06	Novartis Ag	Antikörperderivate
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
JP3024311B2 (ja) *	1991-10-03	2000-03-21	味の素株式会社	Ｉｌ−２受容体重鎖に結合するポリペプチド
US5474771A (en)	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en)	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5817310A (en)	1991-12-02	1998-10-06	Cor Therapeutics, Inc.	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
ATE249840T1 (de) *	1991-12-13	2003-10-15	Xoma Corp	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) *	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
US5777085A (en) *	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en)	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
WO1993016185A2 (en) *	1992-02-06	1993-08-19	Creative Biomolecules, Inc.	Biosynthetic binding protein for cancer marker
GB9203459D0 (en) *	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) *	1992-03-11	1995-02-07	Ciba Corning Diagnostics Corp.	MN gene and protein
US7381803B1 (en)	1992-03-27	2008-06-03	Pdl Biopharma, Inc.	Humanized antibodies against CD3
US6129914A (en) *	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US6033667A (en) *	1992-05-05	2000-03-07	Cytel Corporation	Method for detecting the presence of P-selectin
US5397703A (en) *	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5874082A (en) *	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6066718A (en) *	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) *	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) *	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP3095175B2 (ja)	1992-11-13	2000-10-03	アイデックファーマシューティカルズコーポレイション	Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
CA2149326C (en) *	1992-11-13	2007-04-17	Mitchell E. Reff	Fully impaired consensus kozak sequences for mammalian expression
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
EP0678122B1 (en) *	1993-01-12	1999-07-28	Biogen, Inc.	Recombinant anti-vla4 antibody molecules
US5817311A (en) *	1993-03-05	1998-10-06	Universite Catholique De Louvain	Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) *	1993-03-05	1999-09-14	Universite Catholique De Louvain	Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) *	1993-03-05	1998-03-24	Universite Catholique Delouvain	LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
WO1994025067A1 (en) *	1993-05-04	1994-11-10	Cytel Corporation	Antibodies to p-selectin and their uses
ATE335072T1 (de)	1993-05-28	2006-08-15	Scripps Research Inst	Methoden für inhibition der cd14-abhängigen zellaktivierung
TW458985B (en) *	1993-05-31	2001-10-11	Chugai Pharmaceutical Co Ltd	Reconstructed human antibody against human interleukin-6
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
US5914110A (en) *	1993-09-07	1999-06-22	Smithkline Beecham Corporation	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en)	1993-09-07	2002-12-19	Smithkline Beecham P.L.C.	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) *	1993-09-07	1999-07-27	Smithkline Beecham Corporation	DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
SK285556B6 (sk) *	1993-09-07	2007-03-01	Smithkline Beecham Corporation	Fúzny proteín so špecifickou väzbou na ľudský IL-4, molekula nukleovej kyseliny, monoklonálne protilátky, farmaceutická kompozícia a použitie
WO1995014041A1 (fr)	1993-11-19	1995-05-26	Chugai Seiyaku Kabushiki Kaisha	Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines
WO1995015181A1 (en) *	1993-11-30	1995-06-08	Protein Design Labs, Inc.	Reperfusion therapy using antibodies to l-selectin
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
WO1995019790A1 (en) *	1994-01-25	1995-07-27	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule vla-4
US7435802B2 (en)	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0753065B1 (en)	1994-03-29	2003-05-14	Celltech Therapeutics Limited	Antibodies against e-selectin
US5635597A (en) *	1994-05-27	1997-06-03	Affymax Technologies, N.V.	Peptides that bind IL-2 receptors
US5622701A (en) *	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) *	1994-06-17	2007-04-03	Celltech R&D Limited	Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US6048972A (en) *	1994-07-13	2000-04-11	Chugai Pharmaceutical Co., Ltd.	Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (de) *	1994-07-15	1996-01-18	Boehringer Mannheim Gmbh	Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0696455A1 (en) *	1994-08-11	1996-02-14	Cellena (Cell Engineering) A.G.	Transferrin compositions to alleviate the side effects of cytotoxic drugs
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) *	1994-08-31	1998-01-13	Chugai Pharmaceutical Co., Ltd.	Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5693323A (en) *	1994-12-23	1997-12-02	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5811524A (en) *	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6113898A (en) *	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
AU6171196A (en) *	1995-06-07	1996-12-30	Sloan-Kettering Institute For Cancer Research	Therapeutic uses of ta99
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6440418B1 (en)	1995-11-07	2002-08-27	Idec Pharmaceuticals Corporation	Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en)	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
GB9600660D0 (en)	1996-01-12	1996-03-13	Ciba Geigy Ag	Protein
WO1997033617A1 (en) *	1996-03-13	1997-09-18	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
US5882644A (en) *	1996-03-22	1999-03-16	Protein Design Labs, Inc.	Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en)	1996-04-29	2004-03-30	Novartis Ag	Metastasis-associated antigen and antibodies thereto
JP4503706B2 (ja)	1996-06-07	2010-07-14	ポニアードファーマシューティカルズ，インコーポレイティド	グリコシル化が改質されたヒト化抗体
US6534311B2 (en)	1996-07-24	2003-03-18	Novartis Ag	Drosophila melanogaster p70S6 kinase
US6833255B1 (en)	1996-07-24	2004-12-21	Novartis, Ag	Drosophila melanogaster p70 S6 kinase
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
AU725329B2 (en) *	1996-09-02	2000-10-12	Ko Okumura	Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US6013256A (en) *	1996-09-24	2000-01-11	Protein Design Labs, Inc.	Method of preventing acute rejection following solid organ transplantation
KR100847441B1 (ko) *	1996-09-26	2008-07-21	츄가이 세이야꾸 가부시키가이샤	인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
UA76934C2 (en)	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en)	1996-10-10	2011-02-08	Dyadic International (Usa), Inc.	Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en)	1996-11-15	2002-10-31	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en)	1996-11-15	2011-03-22	Trustees Of Tufts College	Human neutralizing antibodies against hemolytic uremic syndrome
EP2371962A3 (en)	1996-12-23	2011-12-21	Immunex Corporation	Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6262238B1 (en) *	1997-01-14	2001-07-17	Roche Diagnostic, Gmbh	Process for modifying the stability of antibodies
US6596850B1 (en)	1998-01-30	2003-07-22	Ixsys, Incorporated	Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en)	1997-01-30	2003-07-08	Ixsys, Incorporated	Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US5986065A (en)	1997-03-10	1999-11-16	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en)	2001-11-21	2003-06-12	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en)	1997-03-10	2006-10-19	Jin-An Jiao	Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en)	1997-03-10	2010-07-06	Genentech, Inc.	Antibodies for inhibiting blood coagulation and methods of use thereof
ZA982371B (en) *	1997-03-21	1998-09-28	Sankyo Co	Humanized anti-human fas antibody
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
DE69829891T2 (de)	1997-04-07	2005-10-06	Genentech, Inc., South San Francisco	Anti-VEGF Antikörper
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
UA74130C2 (uk)	1997-05-15	2005-11-15	Чугаі Сейяку Кабусікі Кайся	ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
EP1724282B1 (en)	1997-05-21	2013-05-15	Merck Patent GmbH	Method for the production of non-immunogenic proteins
DK1019082T4 (da)	1997-10-02	2008-10-27	Max Planck Gesellschaft	Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
JP3992298B2 (ja) *	1997-10-03	2007-10-17	中外製薬株式会社	天然ヒト型化抗体
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
EP1745799B1 (en)	1998-03-04	2015-09-02	The Trustees of The University of Pennsylvania	Compositions and methods of treating tumors
BR9909382A (pt)	1998-04-03	2000-12-05	Chugai Pharmaceutical Co Ltd	Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
PL195870B1 (pl)	1998-08-11	2007-11-30	Biogen Idec Inc	Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
JP4689781B2 (ja) *	1998-09-03	2011-05-25	独立行政法人科学技術振興機構	アミノ酸輸送蛋白及びその遺伝子
PT1113810E (pt)	1998-09-14	2009-03-10	Univ Texas	Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina
DE69922978T2 (de)	1998-10-06	2005-12-08	Emalfarb, Mark Aaron, Jupiter	Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
EP1939215A1 (en)	1998-10-22	2008-07-02	The University of Montana	Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
CA2350058C (en)	1998-11-09	2015-10-13	Idec Pharmaceuticals Corporation	Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
GB9825632D0 (en)	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
US20030035798A1 (en)	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
IL139321A0 (en)	1999-03-03	2001-11-25	Biogen Inc	Methods and compositions for modulating lipid metabolism
GB9906380D0 (en) *	1999-03-19	1999-05-12	Melvin William T	Monoclonal antibodies specific for cypibi
EA006681B1 (ru)	1999-04-22	2006-02-24	Байоджен Айдек Ма Инк.	Применение антагонистов взаимодействия vla-4 и альфа-4-бета-7 с соответствующими альфа-4-лигандами для лечения фиброза
IT1306704B1 (it)	1999-05-26	2001-10-02	Sirs Societa Italiana Per La R	Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
CA2375827C (en)	1999-06-01	2017-01-10	Biogen, Inc.	A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US7144991B2 (en)	1999-06-07	2006-12-05	Aletheon Pharmaceuticals, Inc.	Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en)	1999-06-24	2003-03-11	Ixsys, Inc.	Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en)	1999-07-02	2006-06-01	Chugai Pharmaceutical Co Ltd	Ameliorative agent for low vasopressin concentration
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
DE60038252T2 (de) *	1999-09-30	2009-03-19	Kyowa Hakko Kogyo Co., Ltd.	Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
EP1234031B2 (en)	1999-11-30	2021-11-24	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
DK2140881T3 (da)	1999-12-16	2013-05-06	Biogen Idec Inc	Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
DK1265928T3 (da)	2000-01-27	2010-11-15	Medimmune Llc	RSV-neutraliserende antistoffer med ultra høj affinitet
ATE373719T1 (de) *	2000-02-03	2007-10-15	Millennium Pharm Inc	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CA2897626C (en)	2000-02-11	2020-03-24	Biogen Idec Ma Inc.	Heterologous polypeptide of the tnf family
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
AU4002001A (en)	2000-03-01	2001-09-12	Med Immune Inc	High potency recombinant antibodies and method for producing them
WO2001070266A2 (en)	2000-03-17	2001-09-27	Millennium Pharmaceuticals, Inc.	Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
US20010046496A1 (en)	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
DE60137417D1 (de)	2000-04-28	2009-03-05	Chugai Pharmaceutical Co Ltd	Zellproliferation-inhibitoren
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
ES2316446T3 (es)	2000-04-29	2009-04-16	University Of Iowa Research Foundation	Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
TWI318983B (en) *	2000-05-02	2010-01-01	Uab Research Foundation	An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en)	2000-05-02	2009-01-13	The Uab Research Foundation	Antibody selective for DR4 and uses thereof
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
DE60143535D1 (de)	2000-10-02	2011-01-05	Novartis Vaccines & Diagnostic	Humane antikörper gegen cd40
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en)	2000-11-28	2006-01-24	Celltech R & D, Inc.	Compositions and methods for diagnosing or treating psoriasis
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
SK12212003A3 (sk) *	2001-04-06	2004-05-04	University Of Bristol	CD25 väzbová molekula na použitie na prevenciu alebo liečenie niektorých ochorení u pacientov rezistentných na liečbu steroidmi
IL158376A0 (en)	2001-04-13	2004-05-12	Biogen Inc	Antibodies to vla-1
US6972324B2 (en)	2001-05-18	2005-12-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Antibodies specific for CD44v6
EP1397387A1 (en) *	2001-05-18	2004-03-17	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Antibodies specific for cd44v6
US7541443B2 (en) *	2001-06-14	2009-06-02	Tolerrx, Inc.	Anti-CD4 antibodies
IL159177A0 (en)	2001-06-20	2004-06-01	Prochon Biotech Ltd	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en)	2001-06-26	2003-01-16	Olson William C.	Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (ja) *	2001-07-10	2011-04-27	三井化学株式会社	熱殺菌方法
US20030138440A1 (en)	2001-07-19	2003-07-24	Fang Fang	Multimeric proteins and methods of making and using same
WO2003014162A1 (en) *	2001-08-03	2003-02-20	Medical & Biological Laboratories Co., Ltd.	ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
AU2002329775C1 (en)	2001-08-17	2011-04-07	Eli Lilly And Company	Assay method for alzheimer's disease
PT1434871T (pt)	2001-09-20	2017-04-05	Immunex Corp	Seleção de células que expressam polipéptidos heteroméricos
RU2305111C2 (ru)	2001-09-25	2007-08-27	Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют	Рекомбинантное антитело против остеопонтина и его применение
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
US20030190705A1 (en) *	2001-10-29	2003-10-09	Sunol Molecular Corporation	Method of humanizing immune system molecules
ATE469176T1 (de) *	2001-11-12	2010-06-15	Merck Patent Gmbh	Modifizierter anti-tnf antikörper
BR0214350A (pt)	2001-11-21	2005-05-10	Univ Pennsylvania	Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
EP1944043A1 (en)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
DK1461300T3 (da)	2001-11-30	2011-10-24	Biogen Idec Inc	Antistoffer mod kemotaktiske monocytproteiner
US7393648B2 (en)	2001-12-03	2008-07-01	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
JP4723810B2 (ja)	2001-12-03	2011-07-13	アレクシオンファーマシューティカルズ，インコーポレイテッド	ハイブリッド抗体
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
CN100522999C (zh) *	2002-02-14	2009-08-05	免疫医疗公司	抗cd20抗体及其融合蛋白和使用方法
PT1478738E (pt) *	2002-02-22	2009-02-16	Progenics Pharm Inc	Anticorpo anti-ccr5
EP3173426A1 (en)	2002-02-25	2017-05-31	Biogen MA Inc.	Administration of agents for the treatment of inflammation
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CN104805090A (zh)	2002-03-13	2015-07-29	生物基因Ma公司	抗αvβ6抗体
US20060171940A1 (en)	2002-03-20	2006-08-03	Celltech R&D Limited	Antibody disulfide isomers, use thereof, and methods of analyzing same
JP4432031B2 (ja) *	2002-03-22	2010-03-17	ズィナイスオペレーションズピーティーワイ．エルティーディー．	インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
ATE473284T1 (de)	2002-05-14	2010-07-15	Martek Biosciences Corp	Carotinsynthase-gen und dessen verwendung
AU2003240790A1 (en)	2002-05-28	2003-12-12	Pharmacia Corporation	Antibody peg positional isomers, compositions comprising same, and use thereof
ATE483472T1 (de) *	2002-05-30	2010-10-15	Macrogenics Inc	Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
GB0213745D0 (en)	2002-06-14	2002-07-24	Univ Edinburgh	Enzyme
AU2002319236A1 (en)	2002-06-14	2003-12-31	Monier Tadros	Method for the production of protamine
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
AU2002368055B2 (en) *	2002-06-28	2008-09-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
WO2010011999A2 (en)	2008-07-25	2010-01-28	The Regents Of The University Of California	Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
NZ540555A (en)	2002-11-15	2008-04-30	Genmab As	Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
JP2007531505A (ja)	2002-11-27	2007-11-08	ミネルババイオオテクノロジーズコーポレーション	癌（ｍｕｃ１）の診断および治療のための技術および組成物
KR20070055625A (ko)	2002-12-16	2007-05-30	제넨테크, 인크.	이뮤노글로불린 변이체 및 이들의 용도
CA2513113A1 (en)	2003-01-23	2004-08-05	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004207535A1 (en)	2003-01-24	2004-08-12	Elan Pharmaceuticals Inc.	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
US7321065B2 (en)	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
US7619070B2 (en)	2003-04-23	2009-11-17	Medarex, Inc.	Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
AU2004232362C1 (en)	2003-04-23	2008-05-29	E. R. Squibb & Sons, L.L.C.	Compositions and methods for the therapy of inflammatory bowel disease
PL2361928T3 (pl)	2003-05-19	2017-09-29	Prothena Biosciences Limited	Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
DK1639014T3 (da)	2003-06-13	2011-01-17	Biogen Idec Inc	Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
US8153410B2 (en)	2003-07-07	2012-04-10	Fox Chase Cancer Center	Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en)	2003-07-07	2006-07-20	Jaffe Eileen K	Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
PT2784084T (pt)	2003-07-08	2019-10-01	Genentech Inc	Anticorpos antagonistas contra polipéptidos heterólogos il-17a/f
EP1648998B1 (en)	2003-07-18	2014-10-01	Amgen Inc.	Specific binding agents to hepatocyte growth factor
US7834155B2 (en)	2003-07-21	2010-11-16	Immunogen Inc.	CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
GB0321997D0 (en)	2003-09-19	2003-10-22	Novartis Ag	Organic compound
EP1693385A4 (en) *	2003-11-11	2009-11-04	Chugai Pharmaceutical Co Ltd	ANTI-CD47 ANTIBODIES HUMANIZED
AU2004290059A1 (en)	2003-11-12	2005-05-26	Albert Einstein College Of Medicine Of Yeshiva University	Novel sequences encoding hepatitis C virus glycoproteins
EP2070947B1 (en)	2003-12-05	2014-06-11	multimmune GmbH	Therapeutic and diagnostic anti-Hsp70 antibodies
EP1692177A2 (en)	2003-12-08	2006-08-23	Morphotek, Inc.	Antibodies that specifically bind pms2
US20080025913A1 (en)	2003-12-15	2008-01-31	Bowdish Katherine S	Novel Anti-Dc-Sign Antibodies
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
MXPA06007856A (es)	2004-01-07	2007-03-23	Chiron Corp	Anticuerpo monoclonal especifico de factor de estimulacion de colonias de macrofagos (m-csf) y usos del mismo.
US20070280950A1 (en)	2004-01-19	2007-12-06	Medical And Biological Laboratories Co., Ltd.	Inflammatory Cytokine Inhibitors
WO2005081783A2 (en)	2004-01-30	2005-09-09	Dana Farber Cancer Institute	Method for determination and quantification of radiation or genotoxin exposure
AU2005212369B2 (en)	2004-02-10	2011-06-23	Musc Foundation For Research Development	Inhibition of factor B, the alternative complement pathway and methods related thereto
TWI359026B (en)	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
WO2005080431A2 (en)	2004-02-12	2005-09-01	Morphotek, Inc.	Monoclonal antibodies that specifically bind to folate receptor alpha
EP1717250A4 (en)	2004-02-20	2008-10-01	Immuno Biological Lab Co Ltd	MONOCLONAL ANTIBODY AND ITS USE
AU2005224081B2 (en)	2004-03-12	2011-06-30	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7625549B2 (en)	2004-03-19	2009-12-01	Amgen Fremont Inc.	Determining the risk of human anti-human antibodies in transgenic mice
JP2008507257A (ja)	2004-03-19	2008-03-13	アムゲン・インコーポレーテッド	Ｖ遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
DK1734996T3 (da)	2004-04-02	2013-06-10	Univ California	Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
CA2568201C (en)	2004-05-24	2013-07-30	Universitat Zu Koln	Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en)	2004-06-04	2005-12-07	University of Geneva	Novel means and methods for the treatment of hearing loss and phantom hearing
PL2662390T3 (pl)	2004-06-21	2017-12-29	E. R. Squibb & Sons, L.L.C.	Antyciała receptora interferonu alfa I oraz ich zastosowania
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
GEP20105059B (en)	2004-07-26	2010-08-10	Biogen Idec Inc	Anti-cd154 antibodies
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2478458A1 (en)	2004-08-20	2006-02-20	Michael Panzara	Treatment of pediatric multiple sclerosis
FI20041204A0 (fi)	2004-09-16	2004-09-16	Riikka Lund	Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
AU2005291486A1 (en)	2004-10-01	2006-04-13	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Novel antibodies directed to the mammalian EAG1 ion channel protein
CA2943949C (en)	2004-10-06	2020-03-31	Mayo Foundation For Medical Education And Research	B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
EA012162B1 (ru)	2004-10-22	2009-08-28	Эмджен Инк.	Способ рефолдинга рекомбинантных антител
CA2584859C (en)	2004-10-25	2017-11-07	Merck & Co., Inc.	Anti-addl antibodies and uses thereof
JP2008520717A (ja)	2004-11-19	2008-06-19	バイオジェン・アイデック・エムエイ・インコーポレイテッド	多発性硬化症についての処置
WO2006066089A1 (en)	2004-12-15	2006-06-22	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
EP2028193B1 (en)	2005-01-05	2012-03-07	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
NZ555937A (en)	2005-01-27	2009-05-31	Childrens Hosp & Res Ct Oak	GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US8088579B2 (en)	2005-02-14	2012-01-03	University Of Iowa Research Foundation	Complement factor H for diagnosis of age-related macular degeneration
US20090124993A1 (en)	2005-02-17	2009-05-14	Burkly Linda C	Treating neurological disorders
EP1860119B1 (en)	2005-02-28	2011-08-03	Institute for Antibodies Co., Ltd.	ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
WO2006094134A2 (en)	2005-03-02	2006-09-08	Biogen Idec Ma Inc.	Kim-1 antibodies for treatment of th2-mediated conditions
AU2006223301B2 (en)	2005-03-10	2010-11-04	Eisai, Inc.	Anti-mesothelin antibodies
AU2006226192A1 (en)	2005-03-19	2006-09-28	Medical Research Council	Improvements in or relating to treatment and prevention of viral infections
PT2343320T (pt)	2005-03-25	2018-01-23	Gitr Inc	Anticorpos anti-gitr e as suas utilizações
CA2610292C (en)	2005-03-30	2015-06-02	Minerva Biotechnologies Corporation	Proliferation of muc1 expressing cells
ES2720288T3 (es)	2005-03-30	2019-07-19	Minerva Biotechnologies Corp	Proliferación de células que expresan MUC1
CN102989012B (zh)	2005-03-31	2015-05-13	通用医疗公司	监测和调制hgf/hgfr活性
US8124350B2 (en)	2005-04-04	2012-02-28	Biogen Idec Ma Inc.	Methods and products for evaluating an immune response to a therapeutic protein
CA2607444C (en)	2005-04-22	2015-03-10	Morphotek, Inc.	Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
JP2008538700A (ja)	2005-04-22	2008-11-06	モルフォテック、インク．	免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
US20090041783A1 (en)	2005-04-28	2009-02-12	Mochida Pharmaceutical Co., Ltd.	Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006117782A2 (en)	2005-05-04	2006-11-09	Quark Pharmaceuticals, Inc.	Recombinant antibodies against cd55 and cd59 and uses thereof
BRPI0608604B8 (pt)	2005-05-10	2021-05-25	Incyte Corp	moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
AU2006247188A1 (en)	2005-05-18	2006-11-23	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against chlamydia infection
WO2006125207A2 (en)	2005-05-19	2006-11-23	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
CA2610340C (en)	2005-05-26	2016-02-16	Vernon Michael Holers	Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
ES2605945T3 (es)	2005-05-27	2017-03-17	Biogen Ma Inc.	Anticuerpos de unión a Tweak
EP1899376A2 (en)	2005-06-16	2008-03-19	The Feinstein Institute for Medical Research	Antibodies against hmgb1 and fragments thereof
CA2611519A1 (en)	2005-06-17	2006-12-28	Tolerx, Inc.	Ilt3 binding molecules and uses therefor
ATE446972T1 (de) *	2005-06-21	2009-11-15	Xoma Technology Ltd	Il-1 bindende antikörper und fragmente davon
CN102875681A (zh)	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	抗-αvβ6抗体及其用途
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
KR20080035653A (ko)	2005-07-22	2008-04-23	프로제닉스 파머슈티컬스, 인코포레이티드	Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
JP5457671B2 (ja)	2005-07-28	2014-04-02	ノバルティスアーゲー	Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8193328B2 (en)	2005-09-08	2012-06-05	Philadelphia Health & Education Corporation	Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
EP1934605B1 (en)	2005-09-22	2014-03-26	Prosci Incorporated	Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CA2627309A1 (en)	2005-10-28	2007-05-03	Meiji Seika Kaisha, Ltd.	Pseudomonas aeruginosa outer membrane protein pa5158
WO2007051077A2 (en)	2005-10-28	2007-05-03	The Regents Of The University Of California	Methods and compounds for lymphoma cell detection and isolation
NZ608431A (en)	2005-11-01	2014-11-28	Abbvie Biotechnology Ltd	Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP1957541A2 (en)	2005-11-21	2008-08-20	Laboratoires Serono SA	Compositions and methods of producing hybrid antigen binding molecules and uses thereof
KR20140087058A (ko)	2005-11-30	2014-07-08	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
CN103638522A (zh)	2006-01-18	2014-03-19	通用医疗公司	增强淋巴功能的方法
WO2007096396A2 (en)	2006-02-22	2007-08-30	University Of Zurich	Methods for treating autoimmune or demyelinating diseases
JP2009534297A (ja)	2006-03-10	2009-09-24	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
EP2006379B1 (en)	2006-03-23	2016-08-31	Tohoku University	High functional bispecific antibody
WO2007114340A1 (ja)	2006-03-30	2007-10-11	Meiji Seika Kaisha, Ltd.	緑膿菌の外膜タンパク質ｐａ０４２７
NZ610566A (en)	2006-04-05	2014-09-26	Abbvie Biotechnology Ltd	Antibody purification
EP2708242A3 (en)	2006-04-10	2014-03-26	Abbott Biotechnology Ltd	Uses and compositions for treatment of ankylosing spondylitis
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2666472A3 (en)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Uses and compositions for treatment of psoriatic arthritis
CN101494978A (zh)	2006-05-25	2009-07-29	比奥根艾迪克Ma公司	治疗中风的方法
ATE553130T1 (de)	2006-05-31	2012-04-15	Astellas Pharma Inc	Humanisierter anti-human-osteopontin-antikörper
JP2009538924A (ja)	2006-06-01	2009-11-12	エランファーマシューティカルズ，インコーポレイテッド	Ａｐｐの神経活性断片
US8101721B2 (en)	2006-06-15	2012-01-24	Fibron Ltd.	Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US7777008B2 (en)	2006-06-19	2010-08-17	Tolerx, Inc.	ILT3 binding molecules and uses therefor
TWI527603B (zh)	2006-06-30	2016-04-01	艾伯維生物技術有限責任公司	自動注射裝置
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
US8529911B2 (en)	2006-07-07	2013-09-10	Intercell Austria Ag	Small Streptococcus pyogenes antigens and their use
CA2662905A1 (en)	2006-07-10	2008-01-17	Biogen Idec Ma Inc.	Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2008007648A1 (fr)	2006-07-10	2008-01-17	Institute For Antibodies Co., Ltd.	Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
EP2420252A1 (en)	2006-08-04	2012-02-22	Novartis AG	EPHB3-specific antibody and uses thereof
JP2010502573A (ja)	2006-08-11	2010-01-28	ユニヴァーシティオブメディスンアンドデンティストリーオブニュージャージー	二重増感剤含有ルミネッセンス化合物および結合体、ならびにその使用
TWI454480B (zh)	2006-08-18	2014-10-01	Novartis Ag	催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
TW201516149A (zh)	2006-09-13	2015-05-01	Abbvie Inc	細胞培養改良
EP2500414A1 (en)	2006-09-13	2012-09-19	Abbott Laboratories	Cell culture improvements
EP2083017A4 (en)	2006-09-14	2011-01-12	Med & Biological Lab Co Ltd	ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
FR2906533B1 (fr)	2006-09-28	2013-02-22	Pf Medicament	Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
WO2008052796A1 (en)	2006-11-03	2008-05-08	U3 Pharma Gmbh	Fgfr4 antibodies
CA2669731C (en)	2006-11-10	2016-01-19	Livtech Inc.	Anti-human dlk-1 antibody showing anti-tumor activity in vivo
JP5647414B2 (ja)	2006-11-17	2014-12-24	ノバルティスアーゲー	Ｌｉｎｇｏ結合分子およびその医薬用使用
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8288110B2 (en)	2006-12-04	2012-10-16	Perkinelmer Health Sciences, Inc.	Biomarkers for detecting cancer
EP2101816B1 (en)	2006-12-07	2013-08-14	Novartis AG	Antagonist antibodies against ephb3
WO2008073914A2 (en)	2006-12-10	2008-06-19	Dyadic International Inc.	Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
WO2008083169A2 (en)	2006-12-26	2008-07-10	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
AU2007339762B2 (en)	2006-12-27	2011-03-31	The Johns Hopkins University	Compositions and methods for treating inflammation and auto-immune diseases
ES2533566T3 (es)	2006-12-29	2015-04-13	The Regents Of The University Of Colorado, A Body Corporate	Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos
PL2099826T3 (pl)	2007-01-05	2014-04-30	Univ Zuerich	Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
WO2008084072A2 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
WO2008098139A2 (en)	2007-02-07	2008-08-14	The Regents Of The University Of Colorado	Axl tyrosine kinase inhibitors and methods of making and using the same
HUE031421T2 (hu)	2007-02-16	2017-07-28	Genzyme Corp	Eljárások pajzsmirigy rendellenességek kockázatának azonosítására
PL3067066T3 (pl)	2007-02-23	2019-09-30	Prothena Biosciences Limited	Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej
EP2118300B1 (en)	2007-02-23	2015-05-27	Prothena Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
JP2010519256A (ja)	2007-02-23	2010-06-03	ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク	免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
WO2008110372A1 (en)	2007-03-13	2008-09-18	University Of Zurich	Monoclonal human tumor-specific antibody
EP3524626A1 (en)	2007-03-22	2019-08-14	Biogen MA Inc.	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
HUE031269T2 (en)	2007-04-05	2017-06-28	Morphotek Inc	Methods for inhibiting the binding of endosial ligands
CA2683145C (en)	2007-04-27	2018-06-12	Katherine E. Lewis	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
CA2685805A1 (en)	2007-05-02	2008-11-13	Intercell Ag	Klebsiella antigens
WO2008143797A1 (en)	2007-05-11	2008-11-27	Genzyme Corporation	Methods of producing a secreted protein
US7709215B2 (en)	2007-06-01	2010-05-04	Cytonics Corporation	Method for diagnosing and treating acute joint injury
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
LT2170390T (lt)	2007-06-14	2019-01-10	Biogen Ma Inc.	Natalizumabo antikūnų kompozicijos
CA2690271A1 (en)	2007-06-18	2008-12-24	Intercell Ag	Chlamydia antigens
WO2009000006A1 (en)	2007-06-26	2008-12-31	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H.	Display of binding agents
KR101560843B1 (ko)	2007-06-27	2015-10-15	고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸	페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
AU2008275589B2 (en)	2007-07-12	2013-11-21	Gitr, Inc.	Combination therapies employing GITR binding molecules
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2514762B1 (en)	2007-07-13	2015-04-08	The Johns Hopkins University	B7-DC variants
ES2534490T3 (es)	2007-08-02	2015-04-23	Gilead Biologics, Inc.	Inhibidores de LOX y LOXL2 y usos de los mismos
RU2525133C2 (ru)	2007-08-30	2014-08-10	Дайити Санкио Компани, Лимитед	Антитело к epha2
EP2186892A1 (en) *	2007-09-06	2010-05-19	Osaka University	Anti-cd20 monoclonal antibodies
CA2736661A1 (en)	2007-09-07	2009-03-12	Dyadic International, Inc.	Novel fungal enzymes
EP2185592B1 (en)	2007-09-13	2013-01-23	University Of Zurich Prorektorat Forschung	Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
MX2010002683A (es)	2007-09-14	2010-03-26	Amgen Inc	Poblaciones de anticuerpos homogeneos.
RU2482876C2 (ru)	2007-10-05	2013-05-27	Дженентек, Инк.	Применение антитела против амилоида-бета при глазных заболеваниях
SG187523A1 (en)	2007-10-11	2013-02-28	Daiichi Sankyo Co Ltd	Antibody targeting osteoclast-related protein siglec-15
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
WO2009051220A1 (ja)	2007-10-19	2009-04-23	Immunas Pharma, Inc.	Aβオリゴマーに特異的に結合する抗体およびその利用
US20100330097A1 (en)	2007-11-01	2010-12-30	Hageman Gregory S	Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
MY149546A (en)	2007-11-02	2013-09-13	Novartis Ag	Improved nogo-a binding molecules and pharmaceutical use tereof
CA2703519C (en)	2007-11-09	2017-04-18	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2918605A1 (en)	2007-11-12	2015-09-16	U3 Pharma GmbH	Axl antibodies
EP2220217A2 (en)	2007-11-28	2010-08-25	The Trustees of the University of Pennsylvania	Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
PL2220241T3 (pl)	2007-11-28	2017-06-30	The Trustees Of The University Of Pennsylvania	Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
WO2009079242A2 (en)	2007-12-05	2009-06-25	Massachusetts Institute Of Technology	Aglycosylated immunoglobulin mutants
WO2009078799A1 (en)	2007-12-17	2009-06-25	Marfl Ab	New vaccine for the treatment of mycobacterium related disorders
CN101970468A (zh)	2007-12-25	2011-02-09	明治制果株式会社	绿脓杆菌的ⅲ型分泌***构成蛋白质pa1698
PL2237803T3 (pl)	2007-12-28	2015-12-31	Prothena Therapeutics Ltd	Leczenie i profilaktyka amyloidozy
US8591888B2 (en)	2008-01-11	2013-11-26	Synovex Corporation	Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders
AU2009203350B2 (en) *	2008-01-11	2014-03-13	Gene Techno Science Co., Ltd.	Humanized anti-alpha9 integrin antibodies and the uses thereof
KR101634636B1 (ko)	2008-01-11	2016-06-29	아스텔라스세이야쿠 가부시키가이샤	개량형 인간화 항-인간 α9 인테그린 항체
ES2617604T3 (es)	2008-02-08	2017-06-19	Immunas Pharma, Inc.	Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización
EP2250255A2 (en)	2008-03-04	2010-11-17	The Trustees of the University of Pennsylvania	Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
AU2009224690B2 (en)	2008-03-13	2014-10-09	Biotest Ag	Agent for treating disease
BRPI0909048A2 (pt)	2008-03-13	2015-11-24	Biotest Ag	composição farmacêutica, e, método de tratamento de uma doença autoimune
AU2009235622C9 (en)	2008-03-13	2015-07-02	Biotest Ag	Agent for treating disease
CA2718473A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
WO2009116670A1 (ja)	2008-03-17	2009-09-24	株式会社リブテック	in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
US8840901B2 (en)	2008-03-17	2014-09-23	Universitaetsklinikum Muenster	YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
WO2009119794A1 (ja)	2008-03-27	2009-10-01	タカラバイオ株式会社	感染症予防、治療剤
BRPI0906903B8 (pt)	2008-04-11	2021-05-25	Seattle Genetics Inc	anticorpo monoclonal e método de detecção da expressão de cd70
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
CA2723197C (en)	2008-05-02	2017-09-19	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP3384919A1 (en)	2008-06-02	2018-10-10	Dana Farber Cancer Institute, Inc.	Cs1 peptides
KR20110038047A (ko)	2008-06-20	2011-04-13	고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸	산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
CA2728004C (en)	2008-06-25	2022-05-24	Esbatech, An Alcon Biomedical Research Unit Llc	Humanization of rabbit antibodies using a universal antibody framework
PL2307458T3 (pl)	2008-06-25	2018-08-31	Esbatech, An Alcon Biomedical Research Unit Llc	Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914319B8 (pt)	2008-06-25	2021-05-25	Esbatech Alcon Biomed Res Unit	imunoligante que se liga especificamente ao tnf alfa humano e composição
PT2824100T (pt)	2008-07-08	2018-05-10	Incyte Holdings Corp	1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
JP5773650B2 (ja)	2008-07-16	2015-09-02	株式会社医学生物学研究所	抗ヒトｃｌｃｐ１抗体とその用途
CA2732715C (en)	2008-08-01	2015-04-07	Kusuki Nishioka	Treatment agent or preventative agent for osteoarthritis
US8795981B2 (en)	2008-08-08	2014-08-05	Molecular Devices, Llc	Cell detection
US8417011B2 (en)	2008-09-18	2013-04-09	Molecular Devices (New Milton) Ltd.	Colony detection
EP2172485A1 (en)	2008-10-01	2010-04-07	Pierre Fabre Medicament	Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2010040029A1 (en)	2008-10-02	2010-04-08	Celtaxsys, Inc.	Methods of modulating the negative chemotaxis of immune cells
KR20140101876A (ko)	2008-10-09	2014-08-20	미네르바 바이오테크놀로지 코포레이션	세포내에서 다능성을 유도하기 위한 방법
DK3199553T3 (da)	2008-10-29	2019-07-22	Circular Commitment Company	Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US8940290B2 (en)	2008-10-31	2015-01-27	The Trustees Of The University Of Pennsylvania	Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
US9469691B2 (en)	2008-12-02	2016-10-18	Pierre Fabre Medicament	Anti-cMET antibody
AR074439A1 (es)	2008-12-02	2011-01-19	Pf Medicament	Anticuerpo anti-cmet (receptor c-met)
MX2011006422A (es)	2008-12-19	2011-09-15	Panima Pharmaceuticals Ag	Autoanticuerpos humanos anti-alfa-sinucleina.
US8313915B2 (en)	2009-01-21	2012-11-20	Gundersen Lutheran Medical Foundation, Inc.	Early detection of canine lyme disease by specific peptides and antibodies
WO2010085590A1 (en)	2009-01-23	2010-07-29	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
EP2424882A2 (en)	2009-02-05	2012-03-07	Intercell AG	Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en)	2009-02-13	2010-08-19	Intercell Ag	Nontypable haemophilus influenzae antigens
US20110306069A1 (en)	2009-02-19	2011-12-15	Qingyu Wu	Corin As A Marker For Heart Failure
CN105837691B (zh)	2009-03-10	2021-06-29	贝勒研究院	靶向抗原呈递细胞的癌症疫苗
MX2011009438A (es)	2009-03-10	2012-04-02	Baylor Res Inst	Anticuerpos anti-cd40 y usos de los mismos.
DK2406290T3 (da)	2009-03-10	2017-09-11	Baylor Res Inst	Cancervacciner, som er målrettet mod antigenpræsenterende celler
JP5725508B2 (ja)	2009-03-25	2015-05-27	国立大学法人東北大学	Ｌｈ型二重特異性抗体
KR101690340B1 (ko)	2009-04-09	2016-12-27	다이이찌 산쿄 가부시키가이샤	항 Ｓｉｇｌｅｃ-15 항체
EP3061460A1 (en)	2009-04-10	2016-08-31	Tufts Medical Center, Inc.	Par-1 activation by metalloproteinase-1 (mmp-1)
DK2419447T3 (da)	2009-04-17	2017-09-25	Immunas Pharma Inc	Antistoffer, der specifikt binder til a beta-oligomerer og anvendelse deraf
SG175279A1 (en)	2009-04-29	2011-11-28	Abbott Biotech Ltd	Automatic injection device
EP2246364A1 (en)	2009-04-29	2010-11-03	Pierre Fabre Médicament	Anti CXCR4 antibodies for the treatment of HIV
EP2270053A1 (en)	2009-05-11	2011-01-05	U3 Pharma GmbH	Humanized AXL antibodies
CN102575232B (zh)	2009-05-29	2015-07-22	宾夕法尼亚大学托管会	猿腺病毒41及其应用
EP2260864A1 (en)	2009-06-10	2010-12-15	University of Melbourne	Therapeutic applications
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
IN2012DN00303A (da)	2009-07-24	2015-05-08	Univ California
CN102548466A (zh)	2009-07-28	2012-07-04	霍夫曼-拉罗奇有限公司	非侵入性体内光学成像方法
US20120164659A1 (en)	2009-08-05	2012-06-28	Nexigen Gmbh	Human hcv-interacting proteins and methods of use
WO2011024114A1 (en)	2009-08-25	2011-03-03	Ecole Polytechnique Federale De Lausanne (Epfl)	Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (zh)	2009-08-28	2013-10-21	Roche Glycart Ag	人類化抗ｃｄｃｐ１抗體
CA2772199A1 (en)	2009-08-31	2011-03-03	Amplimmune, Inc.	B7-h4 fusion proteins and methods of use thereof
AU2010291985B2 (en)	2009-09-14	2016-05-05	The Regents Of The University Of Colorado	Modulation of yeast-based immunotherapy products and responses
EP2305285A1 (en)	2009-09-29	2011-04-06	Julius-Maximilians-Universität Würzburg	Means and methods for treating ischemic conditions
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
EP2308897A1 (en)	2009-10-09	2011-04-13	Pierre Fabre Medicament	Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP3349010A1 (en)	2009-10-11	2018-07-18	Biogen MA Inc.	Anti-vla-4 related assays
US8921525B2 (en)	2009-11-18	2014-12-30	Tohoku University	Highly-functional mutant of humanized anti-EGFR antibody variable region
EP2332929A1 (en)	2009-11-25	2011-06-15	ArisGen SA	Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
US9872905B2 (en)	2009-12-01	2018-01-23	President And Fellows Of Harvard College	Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
AU2010330907A1 (en)	2009-12-16	2012-06-14	Bosch, Phillip	Methods of treating interstitial cystitis
US9221759B2 (en)	2010-01-13	2015-12-29	Rutgers, The State University Of New Jersey	Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
WO2011091181A1 (en)	2010-01-20	2011-07-28	Tolerx, Inc.	Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525813B1 (en)	2010-01-20	2017-01-04	Merck Sharp & Dohme Corp.	Anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2788527A1 (en)	2010-01-29	2011-08-04	Axis Inc.	Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
CN102821786B (zh)	2010-01-29	2016-01-13	阿克西斯股份有限公司	含有骨关节炎治疗剂的注射液
JP2012246222A (ja)	2010-01-29	2012-12-13	Axis Inc	変形性関節症治療剤または予防剤を製造するための使用
EP2531613A2 (en)	2010-02-02	2012-12-12	Abbott Biotechnology Ltd.	Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
BR112012019780A2 (pt)	2010-02-08	2020-09-01	Agensys, Inc.	conjugados de fármaco e anticorpo (adc) que ligam a proteínas 161p2f10b
SG183356A1 (en)	2010-02-18	2012-09-27	Univ California	INTEGRIN aVß8 NEUTRALIZING ANTIBODY
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
CA2791538C (en) *	2010-03-03	2019-04-16	Neil R. Cashman	Oligomer-specific amyloid beta epitope and antibodies
WO2011117392A2 (en)	2010-03-26	2011-09-29	Universitaetsklinikum Muenster	Substitute therapy for glucocorticoids
EP2371863A1 (en)	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer
EP3434694B1 (en)	2010-04-09	2020-12-30	Critical Care Diagnostics, Inc.	Soluble human st-2 antibodies and assays
SG184318A1 (en)	2010-04-16	2012-11-29	Biogen Idec Inc	Anti-vla-4 antibodies
CA2796186C (en)	2010-04-21	2019-04-09	Abbott Biotechnology Ltd.	Wearable automatic injection device for controlled delivery of therapeutic agents
RU2012148816A (ru)	2010-05-07	2014-06-20	Ф. Хоффманн-Ля Рош Аг	Метод диагностики для определения клеток ex vivo
NZ702053A (en)	2010-05-17	2016-01-29	Livtech Inc	Anti-human trop-2 antibody having antitumor activity in vivo
WO2011146727A1 (en)	2010-05-19	2011-11-24	Philip Bosch	Methods of treating interstitial cystitis
EP2592161B1 (en)	2010-07-08	2016-02-03	Honda Motor Co., Ltd.	High frequency heating coil
JP5934203B2 (ja)	2010-07-14	2016-06-15	メルク・シャープ・エンド・ドーム・コーポレイション	抗ａｄｄｌモノクローナル抗体およびこの使用
SI2593128T1 (en)	2010-07-15	2018-08-31	Adheron Therapeutics, Inc.	Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
US8853150B2 (en)	2010-07-29	2014-10-07	Eleven Biotherapeutics, Inc.	Chimeric IL-1 receptor type I antagonists
WO2012016173A2 (en)	2010-07-30	2012-02-02	Ac Immune S.A.	Safe and functional humanized antibodies
JP2012034668A (ja)	2010-08-12	2012-02-23	Tohoku Univ	ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2012027494A1 (en)	2010-08-24	2012-03-01	Regents Of The University Of Minnesota	Bispecific targeting reagents
EP2609431B1 (en)	2010-08-27	2017-05-10	University of Zurich	Method for target and drug validation in inflammatory and/or cardiovascular diseases
JP2013540991A (ja)	2010-08-27	2013-11-07	ユニバーシティ・オブ・チューリッヒ	炎症および／または心血管疾患における新規診断および治療標的
WO2012028697A1 (en)	2010-09-01	2012-03-08	Eth Zürich, Institute Of Molecular Biology And Biophysics	Affinity purification system based on donor strand complementation
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012043747A1 (ja)	2010-09-30	2012-04-05	独立行政法人理化学研究所	グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
US8497138B2 (en)	2010-09-30	2013-07-30	Genetix Limited	Method for cell selection
NZ609984A (en)	2010-10-11	2015-05-29	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
CN103261223B (zh)	2010-10-13	2017-03-29	詹森生物科技公司	人制瘤素m抗体及使用方法
ES2632486T3 (es)	2010-10-18	2017-09-13	Mediapharma S.R.L.	Anticuerpo de unión a ErbB3
JP6121906B2 (ja)	2010-10-22	2017-04-26	シアトルジェネティクス，インコーポレーテッド	アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
RS60565B1 (sr)	2010-10-25	2020-08-31	Biogen Ma Inc	Postupci za određivanje razlika u aktivnosti alfa-4 integrina putem uspostavljanja korelacije sa razlikama u nivoima svcam i/ili smadcam
EP2632953A1 (en)	2010-10-27	2013-09-04	Pierre Fabre Medicament	Antibodies for the treatment of hiv
AU2011321374B2 (en)	2010-10-29	2016-04-28	Daiichi Sankyo Company,Limited	Novel anti-DR5 antibody
EP2640425A2 (en)	2010-11-18	2013-09-25	Beth Israel Deaconess Medical Center, Inc.	Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
KR101919170B1 (ko)	2010-11-19	2018-11-15	에자이 알앤드디 매니지먼트 가부시키가이샤	중화 항-ccl20 항체
EP3075860A1 (en)	2010-11-23	2016-10-05	The Trustees of the University of Pennsylvania	Subfamily e simian adenovirus a1295 and uses thereof
JP6067575B2 (ja)	2010-12-17	2017-01-25	ニューリミューンホールディングエイジー	ヒト抗ｓｏｄ１抗体
WO2012090939A1 (ja)	2010-12-27	2012-07-05	国立大学法人名古屋大学	受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
DK2663580T3 (da)	2011-01-10	2017-03-13	Ct Atlantic Ltd	Kombinationsterapi omfattende tumorassocierede antigenbindende antistoffer
CA2858350A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012103141A1 (en)	2011-01-24	2012-08-02	Abbott Biotechnology Ltd.	Automatic injection devices having overmolded gripping surfaces
WO2012104824A1 (en)	2011-02-04	2012-08-09	Ecole polytechnique fédérale de Lausanne (EPFL)	Therapeutic antibodies targeting app-c99
WO2012107589A1 (en)	2011-02-11	2012-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en)	2011-02-18	2012-08-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
US20140044644A1 (en)	2011-02-21	2014-02-13	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
WO2012119999A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
WO2012120004A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	In vivo selection of therapeutically active antibodies
US10139420B2 (en)	2011-03-09	2018-11-27	ISNERM (Institut National de la Sante et de la Recherche Medicale)	Methods for treating vaso-occlusive crisis using non-modified annexin V
WO2012125680A1 (en)	2011-03-16	2012-09-20	Novartis Ag	Methods of treating vasculitis using an il-17 binding molecule
WO2012123590A1 (de)	2011-03-17	2012-09-20	Miltenyi Biotec Gmbh	Tcralpha/beta-depletierte zellpräparationen
WO2012135132A1 (en)	2011-03-25	2012-10-04	Baylor Research Institute	Compositions and methods to immunize against hepatitis c virus
TW201249867A (en)	2011-04-01	2012-12-16	Astellas Pharma Inc	Novel anti-human il-23 receptor antibody
EP3020428A1 (en)	2011-04-21	2016-05-18	AbbVie Inc.	Wearable automatic injection device for controlled administration of therapeutic agents
TWI561531B (en)	2011-04-25	2016-12-11	Daiichi Sankyo Co Ltd	Anti b7-h3 antibody
DK2704742T3 (da)	2011-05-02	2017-10-23	Millennium Pharm Inc	Formulering til anti-4-7-antistof
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012154889A1 (en)	2011-05-09	2012-11-15	The Cleveland Clinic Foundation	Serum s100b and uses thereof
WO2012163848A1 (en)	2011-05-27	2012-12-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (en)	2011-05-30	2012-12-05	Klinikum rechts der Isar der Technischen Universität München	Means and methods for diagnosing and treating multiple sclerosis
US20140093514A1 (en)	2011-06-03	2014-04-03	University Of Zurich	Magea3 binding antibodies
JP2014524891A (ja)	2011-06-03	2014-09-25	シーティーアトランティックリミテッド	Ｍａｇｅａ３結合抗体
JP6305919B2 (ja)	2011-06-06	2018-04-04	プロセナバイオサイエンシーズリミテッド	Ｍｃａｍアンタゴニスト及び治療の方法
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
US20140120555A1 (en)	2011-06-20	2014-05-01	Pierre Fabre Medicament	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
HUE041391T2 (hu)	2011-06-23	2019-05-28	Biogen Int Neuroscience Gmbh	Anti-alfa-szinukleinkötõ molekulák
DE202011103324U1 (de)	2011-07-12	2012-01-02	Nekonal S.A.R.L.	Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
CN103748222B (zh)	2011-08-11	2015-07-22	安斯泰来制药株式会社	新型抗人ngf抗体
US20140271680A1 (en)	2011-08-12	2014-09-18	Universite Paris-Est Creteil Val De Marne	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2743699A4 (en)	2011-08-12	2015-04-08	Nat Inst Infectious Diseases	METHOD FOR THE TEST, PREVENTION AND TREATMENT OF ASPERGILLUS FUMIGATUS INFECTIOUS DISEASE, AND COMPOSITION
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
AU2012311234B2 (en)	2011-09-19	2017-09-28	Axon Neuroscience Se	Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
GB2495115A (en) *	2011-09-29	2013-04-03	Oxford Plastic Sys Ltd	Base for supporting temporary fence panels or posts.
TW201329105A (zh)	2011-10-04	2013-07-16	Thr Trustees Of Columbia University In The City Of New York	人類ｎｏｔｃｈ１引誘物
EP2764118A1 (en)	2011-10-05	2014-08-13	University of Bremen	Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
WO2013050441A1 (en)	2011-10-05	2013-04-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en)	2011-10-14	2013-04-18	Dana-Farber Cancer Institute, Inc.	Znf365/zfp365 biomarker predictive of anti-cancer response
CN103998598A (zh)	2011-10-17	2014-08-20	米纳瓦生物技术公司	用于干细胞增殖和诱导的培养基
WO2013057313A1 (en)	2011-10-20	2013-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the detection and the treatment of cardiac remodeling
EP2589609A1 (en)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigen binding protein and its use as addressing product for the treatment of cancer
US9427464B2 (en)	2011-11-22	2016-08-30	Chiome Bioscience Inc.	Anti-human TROP-2 antibody having an antitumor activity in vivo
EP2782933A1 (en)	2011-11-22	2014-10-01	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods and pharmaceutical compositions for reducing airway hyperresponse
US9381229B2 (en)	2011-11-28	2016-07-05	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Pharmaceutical composition for use in the treatment of dysfunction associated with aging
EP2602621A1 (en)	2011-12-08	2013-06-12	Julius-Maximilians-Universität Würzburg	LASP-1, a novel urinary marker for transitional cell carcinoma detection
SG11201403134PA (en) *	2011-12-13	2014-07-30	Nordic Nanovector As	Chimeric therapeutic anti - cd37 antibodie hh1
FR2984750B1 (fr)	2011-12-23	2014-01-10	Lfb Biotechnologies	Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
US20150030602A1 (en)	2011-12-23	2015-01-29	Phenoquest Ag	Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2013098419A1 (en)	2011-12-28	2013-07-04	Immunoqure Ag	Method of providing monoclonal auto-antibodies with desired specificity
WO2013098813A1 (en)	2012-01-01	2013-07-04	Qbi Enterprises Ltd.	Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
AU2013216863B2 (en)	2012-02-10	2018-09-06	Seagen Inc.	Detection and treatment of CD30+ cancers
WO2013123114A2 (en)	2012-02-16	2013-08-22	Santarus, Inc.	Antibody formulations
WO2013124419A1 (en)	2012-02-23	2013-08-29	U3 Pharma Gmbh	Her3 inhibitor for modulating radiosensitivity
WO2013129454A1 (ja)	2012-02-28	2013-09-06	アステラス製薬株式会社	新規抗ヒトｉｌ－２３受容体抗体
JO3787B1 (ar)	2012-03-15	2021-01-31	Janssen Biotech Inc	أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
EP2828284B1 (en)	2012-03-20	2019-05-08	Biogen MA Inc.	Jcv neutralizing antibodies
JP6059205B2 (ja)	2012-03-30	2017-01-11	第一三共株式会社	ＣＤＲ改変抗Ｓｉｇｌｅｃ−１５抗体
CA2868965A1 (en)	2012-03-30	2013-10-03	Daiichi Sankyo Company, Limited	Anti-siglec-15 antibody
EP2833900B1 (en)	2012-04-01	2018-09-19	Technion Research & Development Foundation Limited	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CN103382223B (zh)	2012-04-01	2015-06-10	上海益杰生物技术有限公司	针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
CA2869394A1 (en)	2012-04-02	2013-10-10	Gundersen Lutheran Health System, Inc.	Reagents, methods, and kits for the classification of cancer
WO2013154206A1 (ja)	2012-04-09	2013-10-17	第一三共株式会社	抗ｆｇｆｒ２抗体
CN104768973B (zh)	2012-04-27	2019-01-22	第一三共株式会社	抗robo4抗体
US9062120B2 (en)	2012-05-02	2015-06-23	Janssen Biotech, Inc.	Binding proteins having tethered light chains
EP2848633B1 (en)	2012-05-11	2019-02-06	Microbial Chemistry Research Foundation	Anti-cxadr antibody
JP6122948B2 (ja)	2012-05-15	2017-04-26	モルフォテック，インコーポレイテッド	胃癌の治療のための方法
BR112014028684A2 (pt)	2012-05-18	2017-07-25	Univ Pennsylvania	subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
WO2013174834A1 (en)	2012-05-22	2013-11-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating focal segmental glomerulosclerosis
IN2014KN02831A (da)	2012-05-24	2015-05-08	Mountgate Group Ltd
EP4019041B1 (en)	2012-07-13	2022-12-28	The Trustees of the University of Pennsylvania	Toxicity management for anti-tumor activity of cars
PL2875049T3 (pl)	2012-07-18	2019-07-31	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
CN104582717B (zh)	2012-07-19	2018-03-13	雷德伍德生物科技股份有限公司	对cd22有特异性的抗体及其使用方法
AU2013297478B2 (en)	2012-07-30	2018-12-20	Medical & Biological Laboratories Co., Ltd.	Monoclonal antibody against human midkine
PL3489261T3 (pl)	2012-08-24	2021-08-16	The Regents Of The University Of California	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI660972B (zh)	2012-09-10	2019-06-01	愛爾蘭商尼歐托普生物科學公司	抗ｍｃａｍ抗體及相關使用方法
SG11201501924UA (en)	2012-09-13	2015-05-28	Chugai Pharmaceutical Co Ltd	Gene knock-in non-human animal
EP2711016A1 (en)	2012-09-21	2014-03-26	Covagen AG	Novel IL-17A binding molecules and medical uses thereof
RS57120B1 (sr)	2012-10-03	2018-06-29	Chiome Bioscience Inc	Anti-humano dlk-1 antitelo koje ima in vivo aktivnost protiv tumora
EP3677310A1 (en)	2012-10-08	2020-07-08	St. Jude Children's Research Hospital	Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
SI2907824T1 (en)	2012-10-11	2018-06-29	Daiichi Sankyo Company, Limited	THE HEALTHY KJUBIER OF THE PROTITEL
DE102012020496A1 (de)	2012-10-18	2014-04-24	Charité - Universitätsmedizin Berlin	Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
US9872924B2 (en)	2012-10-19	2018-01-23	Daiichi Sankyo Company, Limited	Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014064203A1 (en)	2012-10-26	2014-05-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
JP6694712B2 (ja)	2012-11-01	2020-05-20	マックス−デルブルック−セントラムフアーモレキュラーレメデジン	Ｃｄ２６９（ｂｃｍａ）に対する抗体
WO2014068139A1 (en)	2012-11-05	2014-05-08	Pierre Fabre Medicament	Novel antigen binding proteins and their use as addressing product for the treatment of cancer
EP2917347B1 (en)	2012-11-08	2019-01-02	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods and pharmaceutical compositions for the treatment of bone metastases
AR093445A1 (es)	2012-11-14	2015-06-10	Regeneron Pharma	Metodos para tratar el cancer de ovario con antagonistas de dll4
WO2014093396A1 (en)	2012-12-10	2014-06-19	Biogen Idec Ma Inc.	Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US20160185847A1 (en)	2012-12-17	2016-06-30	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
WO2014100602A1 (en)	2012-12-20	2014-06-26	Hospital For Special Surgery	Treatment of egf-receptor dependent pathologies
LT2935326T (lt)	2012-12-21	2020-12-10	Biogen Ma Inc.	Žmogaus antikūnai prieš tau baltymą
JP6407165B2 (ja)	2012-12-31	2018-10-17	ニューリミューンホールディングエイジー	ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
EP2752426A1 (en)	2013-01-03	2014-07-09	Covagen AG	Human serum albumin binding compounds and fusion proteins thereof
MX2015009547A (es)	2013-01-28	2015-11-25	Evec Inc	Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
US20150377888A1 (en)	2013-02-01	2015-12-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
JP6357113B2 (ja)	2013-02-08	2018-07-11	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
WO2014124677A1 (en)	2013-02-15	2014-08-21	Esbatech - A Novartis Company Llc	Acceptor framework for cdr grafting
EP2958939A1 (en)	2013-02-20	2015-12-30	ESBATech - a Novartis Company LLC	Acceptor framework for cdr grafting
FR3004184B1 (fr)	2013-02-26	2016-03-18	Agronomique Inst Nat Rech	Anticorps anti-gluten desamide et utilisations.
US9429584B2 (en)	2013-02-28	2016-08-30	National Cancer Center	Antibody against insoluble fibrin
ES2811060T3 (es)	2013-03-08	2021-03-10	Univ Osaka	Anticuerpo contra péptido codificado por exón-21 de periostina y composición farmacéutica para prevenir o tratar enfermedades asociadas a inflamación que contienen el mismo
AU2014243839B2 (en)	2013-03-13	2019-01-03	Buzzard Pharmaceuticals AB	Chimeric cytokine formulations for ocular delivery
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
US10081673B2 (en)	2013-03-14	2018-09-25	Ffe Therapeutics Llc	Compositions and methods for treating angiogenesis-related disorders
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2014144466A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
JP2016515120A (ja)	2013-03-15	2016-05-26	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
US10035860B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
PE20160690A1 (es)	2013-03-18	2016-08-14	Biocerox Prod Bv	Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
US9969804B2 (en)	2013-04-01	2018-05-15	The Regents Of The University Of California	Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin
WO2014174596A1 (ja)	2013-04-23	2014-10-30	株式会社医学生物学研究所	ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9717648B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140974B (zh)	2013-05-08	2017-09-29	科济生物医药（上海）有限公司	编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CA2952390A1 (en)	2013-06-20	2014-12-24	The Trustees Of The University Of Pennsylvania	Methods for diagnosing pancreatic cancer
CN112358548A (zh)	2013-07-03	2021-02-12	因美诺克股份公司	人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
WO2015003114A1 (en)	2013-07-05	2015-01-08	University Of Washington Through Its Center For Commercialization	Soluble mic neutralizing monoclonal antibody for treating cancer
WO2015001082A1 (en)	2013-07-05	2015-01-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
TR201906969T4 (tr)	2013-08-09	2019-06-21	Astellas Pharma Inc	Yeni anti-insan tslp reseptör antikoru.
US20160216262A1 (en)	2013-09-12	2016-07-28	Institut National De La Sante Et De La Recherche Medicale	Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
AU2014322988B2 (en)	2013-09-20	2018-12-06	Westfaelische Wilhelms-Universitaet Muenster	Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
EP3049438B1 (en)	2013-09-24	2018-07-25	The Feinstein Institute for Medical Research	Peptides inhibiting cold-inducible rna binding protein activity
US9974788B2 (en)	2013-09-26	2018-05-22	Beth Israel Deaconess Medical Center, Inc.	Inhibition of SGK1 in the treatment of heart conditions
MX2016003643A (es)	2013-09-30	2016-12-20	Daiichi Sankyo Co Ltd	Anticuerpo anti-lps o11.
EP3052131B1 (en)	2013-10-01	2018-12-05	Mayo Foundation for Medical Education and Research	Methods for treating cancer in patients with elevated levels of bim
EP3056215B1 (en)	2013-10-08	2019-11-20	Daiichi Sankyo Company, Limited	Combination of anti-fgfr2 antibody and other agent
MA39090B2 (fr)	2013-11-06	2021-10-29	Janssen Biotech Inc	Anticorps anti-ccl17
WO2015068781A1 (ja)	2013-11-06	2015-05-14	国立大学法人大阪大学	インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
JP2016538286A (ja)	2013-11-15	2016-12-08	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	膵臓癌を処置するための方法及び医薬組成物
WO2015082446A1 (en)	2013-12-02	2015-06-11	F. Hoffmann-La Roche Ag	Treatment of cancer using an anti-cdcp1 antibody and a taxane
MX2016008520A (es)	2013-12-24	2016-11-30	Astellas Pharma Inc	Anticuerpo bdca-2 antihumano novedoso.
KR102088169B1 (ko)	2013-12-25	2020-03-12	다이이찌 산쿄 가부시키가이샤	항 trop2 항체-약물 컨쥬게이트
AU2015205327B2 (en)	2014-01-09	2019-02-14	Hadasit Medical Research Services And Development Ltd.	Improved cell compositions and methods for cancer therapy
JP7037884B2 (ja)	2014-01-13	2022-03-17	ベイラーリサーチインスティテュート	Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN104774264B (zh)	2014-01-15	2018-09-14	上海易乐生物技术有限公司	抗人proBDNF单克隆抗体及其在疼痛中的作用
KR102190548B1 (ko)	2014-01-31	2020-12-14	다이이찌 산쿄 가부시키가이샤	항-her2 항체-약물 접합체
WO2015124588A1 (en)	2014-02-18	2015-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
WO2015124570A1 (en)	2014-02-18	2015-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3415160B1 (en)	2014-03-04	2021-08-18	Klinikum der Universität München	Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2015140351A1 (en)	2014-03-21	2015-09-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing myelination
EP3122768A2 (en)	2014-03-27	2017-02-01	Yeda Research and Development Co. Ltd.	T-cell receptor cdr3 peptides and antibodies
KR20240008415A (ko)	2014-04-10	2024-01-18	다이이찌 산쿄 가부시키가이샤	항her3 항체-약물 콘주게이트
WO2015164743A2 (en)	2014-04-24	2015-10-29	Dana-Farber Cancer Institute, Inc.	Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
LT3134124T (lt)	2014-04-25	2019-05-27	Pierre Fabre Médicament	Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
MA53069B1 (fr)	2014-04-25	2022-04-29	Pf Medicament	Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
SI3134125T1 (sl)	2014-04-25	2020-02-28	Pierre Fabre Medicament	Konjugat zdravila s protitelesom in uporaba le-tega za zdravljenje raka
US11427647B2 (en)	2014-04-27	2022-08-30	Famewave Ltd.	Polynucleotides encoding humanized antibodies against CEACAM1
AP2016009564A0 (en)	2014-04-27	2016-11-30	Ccam Biotherapeutics Ltd	Humanized antibodies against ceacam1
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
EP3160493A4 (en)	2014-06-26	2018-04-11	Yale University	Compositions and methods to regulate renalase in the treatment of diseases and disorders
CN105315375B (zh)	2014-07-17	2021-04-23	恺兴生命科技(上海)有限公司	靶向cld18a2的t淋巴细胞及其制备方法和应用
ES2825708T3 (es)	2014-07-17	2021-05-17	Univ Pennsylvania	Métodos para usar exosomas para monitorizar el estado de órgano trasplantado
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
SG10201902850TA (en)	2014-09-30	2019-04-29	Neurimmune Holding Ag	Human-derived anti-dipeptide repeats (dprs) antibody
JP2017531642A (ja)	2014-10-03	2017-10-26	マサチューセッツインスティテュートオブテクノロジー	エボラ糖タンパク質に結合する抗体およびその使用
WO2016057367A1 (en)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en)	2014-10-09	2020-10-15	Dana-Farber Cancer Institute, Inc.	Multiple-variable IL-2 dose regimen for treating immune disorders
WO2016081835A2 (en)	2014-11-21	2016-05-26	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
US20170319661A1 (en)	2014-12-03	2017-11-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
US20180031579A1 (en)	2015-02-12	2018-02-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
AU2016229238B2 (en)	2015-03-06	2022-06-02	Dana-Farber Cancer Institute, Inc.	PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (en)	2015-03-13	2016-09-14	Ipsen Pharma S.A.S.	Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
EP3271397B1 (en)	2015-03-18	2021-03-03	The Johns Hopkins University	Inhibitory monoclonal antibody targeting potassium channel kcnk9
EP3273981B1 (en)	2015-03-24	2020-04-29	INSERM - Institut National de la Santé et de la Recherche Médicale	Method and pharmaceutical composition for use in the treatment of diabetes
US10214591B1 (en)	2015-04-03	2019-02-26	Alienor Farma	Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
EP3283108B1 (en)	2015-04-13	2020-10-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
JP2018519248A (ja)	2015-04-22	2018-07-19	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｔｈ１７媒介性疾患の処置のための方法及び医薬組成物
CA2987877A1 (en)	2015-06-01	2016-12-08	Medigene Immunotherapies Gmbh	T-cell receptor specific antibodies
US10858760B2 (en)	2015-06-01	2020-12-08	Medigene Immunotherapies Gmbh	T cell receptor library
EA201792661A1 (ru)	2015-06-01	2018-05-31	Медиджин Иммьюнотерапиз Гмбх	Способ получения антител против т-клеточного рецептора
US11384104B2 (en)	2015-06-19	2022-07-12	Centurion Biopharma Corporation	Delivery systems for controlled drug release
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
BR112017027690A2 (pt)	2015-06-29	2018-10-09	Daiichi Sankyo Co Ltd	método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
ES2944982T3 (es)	2015-08-05	2023-06-27	Janssen Biotech Inc	Anticuerpos anti-CD154 y métodos para utilizarlos
US11078251B2 (en)	2015-09-18	2021-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
DK3353196T3 (da)	2015-09-22	2023-02-20	Inst Nat Sante Rech Med	Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
FI3354729T3 (fi)	2015-09-24	2024-04-23	Daiichi Sankyo Co Ltd	Anti-garp-vasta-aine
EA037882B1 (ru)	2015-09-30	2021-05-31	Янссен Байотек, Инк.	Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
WO2017061615A1 (ja)	2015-10-08	2017-04-13	国立大学法人名古屋大学	キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
EP3362093A4 (en)	2015-10-13	2019-05-08	Technion Research & Development Foundation Limited	MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE
US20180305458A1 (en)	2015-10-16	2018-10-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2017072196A1 (en)	2015-10-26	2017-05-04	Pierre Fabre Medicament	Composition for the treatment of igf-1r expressing cancer
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
ITUB20155272A1 (it)	2015-11-02	2017-05-02	Scuola Normale Superiore	Intracellular antibody
WO2017079112A1 (en)	2015-11-03	2017-05-11	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and their uses
CA3002880A1 (en)	2015-11-03	2017-05-11	Glycomimetics, Inc.	Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
ITUB20155097A1 (it)	2015-11-05	2017-05-05	Biouniversa Srl	Anticorpi umanizzati anti-BAG3
WO2017097889A1 (en)	2015-12-10	2017-06-15	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
CN108713027A (zh)	2015-12-17	2018-10-26	詹森生物科技公司	特异性结合hla-dr的抗体及其用途
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
ES2863733T3 (es)	2015-12-23	2021-10-11	Medigene Immunotherapies Gmbh	Generación novedosa de TCR específicos de antígeno
WO2017114976A1 (en)	2015-12-31	2017-07-06	Progastrine Et Cancers S.À R.L.	Compositions and methods for detecting and treating esophageal cancer
JP6962920B2 (ja)	2015-12-31	2021-11-05	プロガストリン、エ、カンセル、エス、アーエル、エルProgastrine Et Cancers S.A R.L.	卵巣癌の検出および治療のための組成物および方法
AU2017204685B2 (en)	2015-12-31	2022-10-13	Progastrine Et Cancers S.À R.L.	Compositions and methods for detecting and treating gastric cancer
EP3202788A1 (en)	2016-02-05	2017-08-09	MediaPharma S.r.l.	Endosialin-binding antibody
JP7063813B2 (ja)	2016-02-15	2022-05-09	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	術後認知機能障害の処置のための方法及び医薬組成物
EP3205663A1 (en)	2016-02-15	2017-08-16	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for inhibiting gene expression
MX2018010445A (es)	2016-03-01	2019-10-17	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	Anticuerpos especificos del receptor de poliovirus humano (rvp).
US11340233B2 (en)	2016-03-07	2022-05-24	Pierre Fabre Medicament	Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
US11921116B2 (en)	2016-03-09	2024-03-05	Memorial Sloan Kettering Cancer Center	Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
ES2911038T3 (es)	2016-03-15	2022-05-17	Inst Nat Sante Rech Med	Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
US20190086392A1 (en)	2016-03-21	2019-03-21	Inserm (Institut National De La Sante Et De La Recherch Medicale)	Methods for diagnosis and treatment of solar lentigo
CN111363041B (zh)	2016-03-23	2022-02-22	苏州创胜医药集团有限公司	新型抗-pd-l1抗体
CA3019145A1 (en)	2016-03-28	2017-10-05	Incyte Corporation	Pyrrolotriazine compounds as tam inhibitors
ITUA20162242A1 (it)	2016-04-01	2017-10-01	St Biochimico Italiano Giovanni Lorenzini Spa	Un nuovo anticorpo anti-erbb2
WO2017182705A1 (en)	2016-04-18	2017-10-26	Faron Pharmaceuticals Oy	Humanized anti clever-1 antibodies and their use
WO2017191100A1 (en)	2016-05-03	2017-11-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of tissue lesions
BR112018073316A2 (pt)	2016-05-11	2019-06-04	Amgen Inc	seleção direta de células que expressam altos níveis de proteínas heteroméricas usando vetores de complementação intragênica da glutamina sintetase
EP3458093A1 (de)	2016-05-20	2019-03-27	Christoph Karl	Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
WO2017202814A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
EP3464357A1 (en)	2016-05-24	2019-04-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
SG11201810697QA (en)	2016-06-07	2018-12-28	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Chimeric antigen receptor and car-t cells that bind bcma
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
ES2883182T3 (es)	2016-07-06	2021-12-07	Prothena Biosciences Ltd	Ensayo para la detección de alfa-sinucleína total y fosforilada en S129
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20190330318A1 (en)	2016-07-25	2019-10-31	Biogen Ma Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
JP2019528437A (ja)	2016-07-28	2019-10-10	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
CN109843916B (zh)	2016-08-12	2023-10-31	詹森生物科技公司	具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
US10669344B2 (en)	2016-08-12	2020-06-02	Janssen Biotech, Inc.	Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
AU2017332721B2 (en)	2016-09-20	2023-11-09	Sara BUHRLAGE	Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
CN109789211A (zh)	2016-10-07	2019-05-21	第一三共株式会社	基于抗her2抗体-药物偶联物施予的耐性癌的治疗
US20190300607A1 (en)	2016-10-12	2019-10-03	Daiichi Sankyo Company, Limited	Composition containing anti-robo4 antibody and other agents
CU20200105A7 (es)	2016-10-13	2021-08-06	Massachusetts Inst Technology	Anticuerpos que se unen a la proteína de envoltura del virus zika
IT201600111877A1 (it)	2016-11-07	2018-05-07	Biouniversa Srl	Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
UA126388C2 (uk)	2016-11-18	2022-09-28	Астеллас Фарма Інк.	Fab-фрагмент антитіла до muc1 людини
EP3552626A4 (en)	2016-12-12	2020-06-10	Daiichi Sankyo Company, Limited	ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
BR112019011988A2 (pt)	2016-12-13	2019-11-05	Astellas Pharma Inc	anticorpo anti-cd73 humana
CN110300761B (zh)	2016-12-15	2023-05-09	国家生物技术研究所公司	抗pcna单克隆抗体及其用途
JP7202185B2 (ja)	2016-12-22	2023-01-11	第一三共株式会社	抗ｃｄ３抗体及び該抗体を含む分子
US20180179490A1 (en)	2016-12-27	2018-06-28	Miltenyi Biotec Gmbh	CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
US11773182B2 (en)	2017-01-05	2023-10-03	The Johns Hopkins University	Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN110382535A (zh)	2017-01-17	2019-10-25	第一三共株式会社	抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
WO2018140510A1 (en)	2017-01-25	2018-08-02	Biogen Ma Inc.	Compositions and methods for treatment of stroke and other cns disorders
KR20190133160A (ko)	2017-02-07	2019-12-02	다이이찌 산쿄 가부시키가이샤	항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
EP3363459A1 (en)	2017-02-17	2018-08-22	Alexander Klimka	Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
CA3092434A1 (en)	2017-02-27	2018-08-30	Caerus Therapeutics, Inc.	Compositions of a novel anti-human ceacam6 antibody and uses thereof
KR20190120764A (ko)	2017-02-28	2019-10-24	갓코 호진 긴키 다이가쿠	항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
EP4095161A1 (en)	2017-03-15	2022-11-30	Tsinghua University	Novel anti-trkb antibodies
JOP20180021A1 (ar)	2017-03-16	2019-01-30	Janssen Biotech Inc	الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TWI782000B (zh)	2017-03-30	2022-11-01	日商第一三共股份有限公司	抗ｇｐｒ２０抗體、其製造方法及其應用
CN110662967A (zh)	2017-03-30	2020-01-07	Ecs前胃泌素股份有限公司	用于检测肺癌的组合物和方法
CN110945025B (zh)	2017-03-30	2023-11-03	Ecs前胃泌素股份有限公司	用于检测***癌的组合物和方法
US10722589B2 (en)	2017-04-03	2020-07-28	Covagen Ag	FGFR3 binding molecules
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3610264A1 (en)	2017-04-13	2020-02-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
CN111201034A (zh)	2017-05-11	2020-05-26	西托戴恩股份有限公司	涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
TWI794230B (zh)	2017-05-15	2023-03-01	日商第一三共股份有限公司	抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
MA52459A (fr)	2017-06-05	2021-03-10	Janssen Biotech Inc	Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
US11820822B2 (en)	2017-06-06	2023-11-21	Dana-Farber Cancer Institute, Inc.	Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US20210145828A1 (en)	2017-06-29	2021-05-20	Rutgers, The State University Of New Jersey	Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
EP3646885A4 (en)	2017-06-30	2021-04-28	National University Corporation Hokkaido University	MEDICINAL PRODUCTS AGAINST OSTEOPOROSIS IN CHILDREN WITHOUT CAUSING GROWTH DISORDERS
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR112020001255A2 (pt)	2017-07-21	2020-07-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	composições imunogênicas de neisseria meningitidis
EP3660155A4 (en)	2017-07-27	2021-04-07	Daiichi Sankyo Company, Limited	ANTI-CD147 ANTIBODY
EP3658582A1 (en)	2017-07-28	2020-06-03	Intrepida Bio, Inc.	Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
CN110945023B (zh)	2017-07-31	2023-08-18	豪夫迈·罗氏有限公司	基于三维结构的人源化方法
EP3444272A1 (en)	2017-08-17	2019-02-20	International-Drug-Development-Biotech	Treatment of ck8 positive cancers in relation with k-ras gene status
JP7395465B2 (ja)	2017-08-23	2023-12-11	マックス－デルブリュック－セントルムフュールモレキュラーメディツィンインデアヘルムホルツ－ゲマインシャフト	キメラ抗原受容体と、ｃｘｃｒ５に結合するｃａｒ－ｔ細胞
MA49987A (fr)	2017-08-23	2020-07-01	Daiichi Sankyo Co Ltd	Préparation de conjugué anticorps-médicament et lyophilisation associée
SG11202000997YA (en)	2017-08-31	2020-03-30	Daiichi Sankyo Co Ltd	Improved method for producing antibody-drug conjugate
CN111065621B (zh)	2017-08-31	2024-01-26	第一三共株式会社	制备抗体-药物缀合物的新方法
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
IL301638B1 (en)	2017-09-29	2024-05-01	Daiichi Sankyo Co Ltd	Conjugation of an antibody with a pyrrolobenzodiazepine derivative
WO2019069561A1 (ja)	2017-10-03	2019-04-11	公益財団法人東京都医学総合研究所	インフルエンザに対する医薬
CA3078436A1 (en)	2017-10-05	2019-04-11	Daiichi Sankyo Company, Limited	Composition for cytotoxic t cell depletion
KR101966362B1 (ko)	2017-10-20	2019-04-05	주식회사 녹십자	항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
US11591385B2 (en)	2017-11-09	2023-02-28	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3717018A1 (en)	2017-11-30	2020-10-07	Centurion BioPharma Corporation	Maytansinoid-based drug delivery systems
PT3717503T (pt)	2017-11-30	2024-01-16	Ladrx Corp	Profármacos de ligação a albumina de derivados de auristatina e
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
CN111670197A (zh)	2017-12-05	2020-09-15	普莱戈斯瑞恩癌症有限责任公司	治疗癌症的抗前胃泌激素抗体与免疫疗法的组合疗法
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
US20190225689A1 (en)	2018-01-22	2019-07-25	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-pd-1 antibodies
TW201940881A (zh)	2018-01-26	2019-10-16	瑞士商Ｅｃｓ前胃泌激素公司	在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3752252A4 (en)	2018-02-12	2021-11-17	Hadasit Medical Research Services and Development Ltd.	MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER THERAPY
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
SG11202008271QA (en)	2018-02-27	2020-09-29	Ecs Progastrin Sa	Progastrin as a biomarker for immunotherapy
CN117903140A (zh)	2018-02-27	2024-04-19	因赛特公司	作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶
CN111836643A (zh)	2018-03-05	2020-10-27	学校法人埼玉医科大学	用于治疗或预防异位骨化的药物组合物
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
US20210164984A1 (en)	2018-04-13	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
EP3781590A1 (en)	2018-04-20	2021-02-24	Medizinische Hochschule Hannover	Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019207066A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for the treatment of sjögren's syndrome
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
US20210130459A1 (en)	2018-05-09	2021-05-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human nectin4
AU2019268022A1 (en)	2018-05-11	2020-11-26	Astellas Pharma Inc.	Nucleic acid for treating mite allergy
SG11202011166UA (en)	2018-05-11	2020-12-30	Astellas Pharma Inc	Nucleic acid for treating crustacean allergy
JP7360766B2 (ja)	2018-05-17	2023-10-13	アステラス製薬株式会社	抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
MA52940A (fr)	2018-05-18	2021-04-28	Incyte Corp	Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MA52773A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Anticorps anti-cd3 et leurs utilisations
JOP20200303A1 (ar)	2018-05-24	2020-11-23	Janssen Biotech Inc	عوامل ربط psma واستخداماتها
JOP20200295A1 (ar)	2018-05-24	2020-11-22	Janssen Biotech Inc	أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
KR20210014660A (ko)	2018-05-28	2021-02-09	다이이찌 산쿄 가부시키가이샤	항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR20210018192A (ko)	2018-05-31	2021-02-17	다이이찌 산쿄 가부시키가이샤	항인간 tlr7 항체
EP3802611A2 (en)	2018-06-01	2021-04-14	Novartis AG	Binding molecules against bcma and uses thereof
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
US20200095322A1 (en)	2018-06-20	2020-03-26	Incyte Corporation	Anti-pd-1 antibodies and uses thereof
US20210277118A1 (en)	2018-06-21	2021-09-09	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
AR117600A1 (es)	2018-06-29	2021-08-18	Incyte Corp	Formulaciones de un inhibidor de axl / mer
WO2020007898A1 (en)	2018-07-04	2020-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating brain injury or neurodegenerative disease
JP7490631B2 (ja)	2018-07-05	2024-05-27	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
KR20210038904A (ko)	2018-07-25	2021-04-08	다이이찌 산쿄 가부시키가이샤	항체-약물 콘쥬게이트의 효과적인 제조 방법
CN112512584A (zh)	2018-07-27	2021-03-16	国立大学法人大阪大学	用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
EP3831853A4 (en)	2018-07-27	2022-06-01	Daiichi Sankyo Company, Limited	ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
AU2019315177A1 (en)	2018-07-31	2021-02-25	Daiichi Sankyo Company, Limited	Treatment of metastatic brain tumor by administration of antibody-drug conjugate
BR112021001750A2 (pt)	2018-08-06	2021-04-27	Daiichi Sankyo Company, Limited	composição farmacêutica
CN112714649A (zh)	2018-09-06	2021-04-27	第一三共株式会社	新型环状二核苷酸衍生物及其抗体药物偶联物
BR112021005246A2 (pt)	2018-09-20	2021-06-15	Daiichi Sankyo Company, Limited	agente terapêutico, e, método de tratamento para câncer
US20230038521A1 (en)	2018-09-21	2023-02-09	National University Corporation Tokyo Medical An D Dental University	Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody
JP2022502431A (ja)	2018-09-27	2022-01-11	ピエール、ファーブル、メディカマン	スルホマレイミドに基づくリンカーおよび対応する複合体
US20220048966A1 (en)	2018-09-28	2022-02-17	Pierre Fabre Medicament	New immunocytokines for the treatment of cancer
CN112839683B (zh)	2018-10-10	2023-11-14	安斯泰来制药株式会社	含有标记部-抗人抗体Fab片段复合物的药物组合物
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
US20210340240A1 (en)	2018-10-18	2021-11-04	INSERM (Institut National de la Santé et de la Recherche Médicale	Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
AU2019369771A1 (en)	2018-10-31	2021-06-03	Astellas Pharma Inc.	Anti-human Fn14 antibody
EP3880706A1 (en)	2018-11-12	2021-09-22	MediaPharma S.r.l.	Bispecific antibodies directed against human 90k and either endosialin or her3
CA3119956A1 (en)	2018-11-14	2020-05-22	Daiichi Sankyo Company, Limited	Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
CN113271942A (zh)	2018-12-11	2021-08-17	第一三共株式会社	抗体-药物缀合物与parp抑制剂的组合
AU2019407426A1 (en)	2018-12-21	2021-07-22	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
BR112021012103A2 (pt)	2018-12-21	2021-09-08	Aim Immunotech Inc.	Composições e métodos para terapia de câncer
WO2020145228A1 (ja)	2019-01-07	2020-07-16	アステラス製薬株式会社	配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体
TW202043256A (zh)	2019-01-10	2020-12-01	美商健生生物科技公司	***新抗原及其用途
KR20210117277A (ko)	2019-01-13	2021-09-28	이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.	인간 넥틴-2에 특이적인 항체
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
CA3125697A1 (en)	2019-01-29	2020-08-06	Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh)	Treating the causative agent in adhesiogenesis
JP2022520088A (ja)	2019-02-13	2022-03-28	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	抗末梢リンパ節アドレッシン抗体およびその使用
WO2020178193A1 (en)	2019-03-01	2020-09-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment of sarcoidosis
WO2020193441A1 (en)	2019-03-22	2020-10-01	Université de Paris	New inhibitors of lrrk2/pp1 interaction
AU2020246448A1 (en)	2019-03-25	2021-10-14	Daiichi Sankyo Company, Limited	Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3950061A4 (en)	2019-03-25	2022-11-16	Daiichi Sankyo Company, Limited	ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
AU2020247119A1 (en)	2019-03-25	2021-09-23	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Enhancement of cytolytic T-cell activity by inhibiting EBAG9
US20220168438A1 (en)	2019-03-27	2022-06-02	Daiichi Sankyo Company, Limited	Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
US20220193064A1 (en)	2019-04-01	2022-06-23	Chiome Bioscience Inc.	Medicament for treating cancer
WO2020206033A1 (en)	2019-04-02	2020-10-08	Kenjockety Biotechnology, Inc.	Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
MA55717A (fr)	2019-04-19	2022-02-23	Janssen Biotech Inc	Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
EP3962529A4 (en)	2019-04-30	2023-11-01	Dana-Farber Cancer Institute, Inc.	METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
CA3133333A1 (en)	2019-04-30	2020-04-30	Brian Scott GARRISON	Chimeric receptors and methods of use thereof
EP3969569A1 (en)	2019-05-14	2022-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
AU2020285681A1 (en)	2019-05-29	2022-01-27	Daiichi Sankyo Company, Limited	Dosage of an antibody-drug conjugate
JP2022538237A (ja)	2019-06-24	2022-09-01	ノバルティスアーゲー	Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
EP4008350A4 (en)	2019-07-26	2023-06-14	Saitama Medical University	ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
CN114375302A (zh)	2019-07-26	2022-04-19	詹森生物科技公司	包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
WO2021019706A1 (ja)	2019-07-31	2021-02-04	国立大学法人信州大学	Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
CN114502196A (zh)	2019-08-01	2022-05-13	因赛特公司	Ido抑制剂的给药方案
EP4007603A1 (en)	2019-08-02	2022-06-08	CytoDyn Inc.	Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
CA3150428A1 (en)	2019-08-12	2021-02-18	Biond Biologics Ltd.	Antibodies against ilt2 and use thereof
EP3792632A1 (en)	2019-09-16	2021-03-17	Vito NV	Immunotherapy markers
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021058744A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021059075A1 (en)	2019-09-27	2021-04-01	Janssen Biotech, Inc.	Anti-ceacam antibodies and uses thereof
TW202128761A (zh)	2019-10-25	2021-08-01	日商第一三共股份有限公司	抗garp抗體與免疫調節劑之組合
PE20221462A1 (es)	2019-11-15	2022-09-21	Pliant Therapeutics Inc	Composiciones y metodos para la activacion de integrinas
BR112022009598A2 (pt)	2019-11-18	2022-08-16	Janssen Biotech Inc	Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
CN112500483B (zh) *	2019-12-10	2022-11-29	西西欧艾(杭州)生物医药有限责任公司	抗血小板膜糖蛋白ib alpha人源化抗体及其应用
CN115135671A (zh)	2019-12-20	2022-09-30	新石生物制药有限公司	抗白介素-23 p19的抗体及其使用方法
TW202135824A (zh)	2020-01-03	2021-10-01	美商英塞特公司	包含ａ２ａ／ａ２ｂ及ｐｄ－１／ｐｄ－ｌ１抑制劑之組合療法
WO2021140173A1 (en)	2020-01-10	2021-07-15	Biouniversa S.R.L.	Methods and uses for treating fibrotic solid tumors with bags inhibitors
EP4100525A1 (en)	2020-02-05	2022-12-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods of treatment of cancer disease by targeting an epigenetic factor
TW202140012A (zh)	2020-02-12	2021-11-01	比利時商健生藥品公司	用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
JP2023519153A (ja)	2020-03-03	2023-05-10	アクティブバイオテックエイビー	組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩
BR112022015283A2 (pt)	2020-03-06	2022-09-20	Daiichi Sankyo Co Ltd	Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos
KR20230017165A (ko)	2020-03-06	2023-02-03	인사이트 코포레이션	Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
WO2021183207A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
EP4233893A3 (en)	2020-03-13	2023-09-27	Janssen Biotech, Inc.	Materials and methods for binding siglec-3/cd33
US11045546B1 (en)	2020-03-30	2021-06-29	Cytodyn Inc.	Methods of treating coronavirus infection
JPWO2021200131A1 (da)	2020-03-30	2021-10-07
EP3889183A1 (en)	2020-04-01	2021-10-06	Pierre Fabre Medicament	A protein complex comprising an immunocytokine
CA3179348A1 (en)	2020-04-06	2021-10-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
CN115397860A (zh)	2020-05-14	2022-11-25	江苏恒瑞医药股份有限公司	抗cd25抗体、其抗原结合片段及其医药用途
US20230192879A1 (en)	2020-05-19	2023-06-22	Institut Curie	Methods for the diagnosis and treatment of cytokine release syndrome
MX2022014938A (es)	2020-05-27	2023-03-06	Janssen Biotech Inc	Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
BR112022023931A2 (pt)	2020-05-27	2023-04-11	Arialys Therapeutics Inc	Derivado de anticorpo nr1 anti-humano
JP2023528417A (ja)	2020-06-04	2023-07-04	ケンジョッケティバイオテクノロジー，インク．	Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
TW202216208A (zh)	2020-06-24	2022-05-01	英商阿斯特捷利康英國股份有限公司	抗體-藥物結合物及atr抑制劑之組合
TW202216207A (zh)	2020-06-24	2022-05-01	英商阿斯特捷利康英國股份有限公司	抗體-藥物結合物及cdk9抑制劑之組合
WO2021260583A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and dna-pk inhibitor
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
JP2023539715A (ja)	2020-06-24	2023-09-19	アストラゼネカユーケーリミテッド	抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
EP4171527A1 (en)	2020-06-25	2023-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of treatment and diagnostic of pathological conditions associated with intense stress
BR112023000711A2 (pt)	2020-07-17	2023-01-31	Daiichi Sankyo Co Ltd	Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
US20230293714A1 (en)	2020-07-20	2023-09-21	Daiichi Sankyo Company, Limited	Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
CN116209681A (zh)	2020-07-29	2023-06-02	詹森生物科技公司	包含hla-g抗原结合结构域的蛋白质及其用途
RU2764216C1 (ru) *	2020-08-10	2022-01-14	Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова"	Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
EP4196227A2 (en)	2020-08-12	2023-06-21	Biond Biologics Ltd.	Antibodies against ilt2 and use thereof
EP4199958A1 (en)	2020-08-24	2023-06-28	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (car)-expressing cells recognizing cea
WO2022043315A1 (en)	2020-08-24	2022-03-03	Charité - Universitätsmedizin Berlin	A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
EP4208259A2 (en)	2020-09-04	2023-07-12	NovaRock Biotherapeutics, Ltd.	Nectin-4 antibodies and uses thereof
EP4210722A1 (en)	2020-09-07	2023-07-19	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods of treatment of inflammatory bowel diseases
JP2023545359A (ja)	2020-09-12	2023-10-30	アストラゼネカ・ユーケイ・リミテッド	抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法
CA3198077A1 (en)	2020-10-05	2022-04-14	Chiome Bioscience Inc.	Medicine for treating cancer
IL301921A (en)	2020-10-09	2023-06-01	Daiichi Sankyo Co Ltd	Combining an antibody-drug conjugate and a selective 1PARP inhibitor
UY39467A (es)	2020-10-13	2022-04-29	Janssen Biotech Inc	Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
US20230416346A1 (en)	2020-10-21	2023-12-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
TW202233672A (zh)	2020-10-22	2022-09-01	美商健生生物科技公司	包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
WO2022097090A1 (en)	2020-11-05	2022-05-12	Novartis Ag	Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
KR20230113564A (ko)	2020-11-06	2023-07-31	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	다낭성 난소 증후군(pcos)의 진단 및 치료 방법
KR20230106645A (ko)	2020-11-11	2023-07-13	다이이찌 산쿄 가부시키가이샤	항체-약물 콘주게이트와 항 SIRPα 항체의 조합
US20230398230A1 (en)	2020-11-12	2023-12-14	Daiichi Sankyo Company, Limited	Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
CR20230244A (es)	2020-11-16	2023-07-12	Astellas Pharma Inc	Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
WO2022112469A1 (en)	2020-11-27	2022-06-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and monitoring of toxic epidermal necrolysis
TW202241436A (zh)	2020-11-30	2022-11-01	美商英塞特公司	抗ｃｄ１９抗體及帕薩昔布（ｐａｒｓａｃｌｉｓｉｂ）之組合療法
WO2022115120A1 (en)	2020-11-30	2022-06-02	Incyte Corporation	Combination therapy with an anti-cd19 antibody and parsaclisib
JPWO2022124247A1 (da)	2020-12-09	2022-06-16
CN117500503A (zh)	2020-12-29	2024-02-02	因赛特公司	包含a2a/a2b抑制剂、pd-1/pd-l1抑制剂和抗cd73抗体的组合疗法
EP4277664A1 (en)	2021-01-13	2023-11-22	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
TW202245844A (zh)	2021-01-13	2022-12-01	紀念斯隆凱特琳癌症中心	抗dll3抗體-藥物結合物
WO2022153212A1 (en)	2021-01-13	2022-07-21	Axon Neuroscience Se	Antibodies neutralizing sars-cov-2
WO2022162518A2 (en)	2021-01-28	2022-08-04	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
US20240141060A1 (en)	2021-01-29	2024-05-02	Novartis Ag	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202241454A (zh)	2021-02-01	2022-11-01	日商第一三共股份有限公司	抗體－免疫賦活化劑共軛物之新穎製造方法
AU2022219681A1 (en)	2021-02-11	2023-09-21	Nectin Therapeutics Ltd.	Antibodies against cd112r and uses thereof
CA3208905A1 (en)	2021-02-12	2022-08-18	Boehringer Ingelheim International Gmbh	Complement c3 antigen binding proteins
US20220378929A1 (en)	2021-02-25	2022-12-01	MediBoston Limted	Anti-her2 antibody-drug conjugates and uses thereof
AU2022229805A1 (en)	2021-03-02	2023-09-21	Dana-Farber Cancer Institute, Inc.	Methods of treating red blood cell disorders
EP4305064A1 (en)	2021-03-12	2024-01-17	Fibrosys S.r.l.	Monoclonal antibodies for the treatment of viral infections
IL305816A (en)	2021-03-12	2023-11-01	Daiichi Sankyo Co Ltd	Glycan and a method for preparing a medicine containing it
EP4314055A1 (en)	2021-03-24	2024-02-07	Janssen Biotech, Inc.	Antibody targeting cd22 and cd79b
IL307168A (en)	2021-03-26	2023-11-01	Janssen Biotech Inc	Humanized antibodies against paired helical strands of TAU protein and their uses
WO2022218998A1 (en)	2021-04-13	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for treating hepatitis b and d virus infection
KR20230170672A (ko)	2021-04-14	2023-12-19	빌라리스 테라퓨틱스 인코포레이티드	항-cd122 항체 및 이의 용도
AR125398A1 (es)	2021-04-22	2023-07-12	Astellas Pharma Inc	Anticuerpo biespecífico anti-cldn4 / anti-cd137
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (zh) *	2021-07-11	2022-02-18	西南石油大学	一种dna图谱算法的改进试验方法
CN118176213A (zh)	2021-08-27	2024-06-11	詹森生物科技公司	抗psma抗体及其用途
AU2022347380A1 (en)	2021-09-15	2024-04-11	Daiichi Sankyo Company, Limited	Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
WO2023041744A1 (en)	2021-09-17	2023-03-23	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
WO2023046322A1 (en)	2021-09-24	2023-03-30	Janssen Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en)	2021-09-30	2023-04-06	Imcheck Therapeutics	Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
TW202330041A (zh)	2021-10-18	2023-08-01	日商第一三共股份有限公司	抗cd37抗體-藥物結合物
AU2022378932A1 (en)	2021-10-27	2024-05-02	Assistance Publique Hopitaux De Marseille	Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
WO2023089527A1 (en)	2021-11-18	2023-05-25	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023089032A1 (en)	2021-11-19	2023-05-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023105528A1 (en)	2021-12-12	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to ceacam1
US20230357392A1 (en)	2021-12-22	2023-11-09	Morphosys Ag	Treatment Paradigm for an Anti-CD19 Antibody Therapy
CA3240724A1 (en)	2021-12-28	2023-07-06	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and atr inhibitor
TW202333800A (zh)	2021-12-28	2023-09-01	英商阿斯特捷利康英國股份有限公司	抗體-藥物結合物及rasg12c抑制劑之組合
WO2023152581A1 (en)	2022-02-09	2023-08-17	Janssen Biotech, Inc.	Method of treating cancer with psmaxcd3 antibody
WO2023166081A1 (en)	2022-03-02	2023-09-07	Heidelberg Immunotherapeutics Gmbh	Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023175614A1 (en)	2022-03-15	2023-09-21	Yeda Research And Development Co. Ltd.	Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
WO2023175483A1 (en)	2022-03-16	2023-09-21	Astrazeneca Uk Limited	A scoring method for an anti-trop2 antibody‑drug conjugate therapy
TW202400140A (zh)	2022-04-27	2024-01-01	日商第一三共股份有限公司	抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
TW202400650A (zh)	2022-05-11	2024-01-01	日商第一三共股份有限公司	抗體與cd47抑制劑之組合
WO2023228095A1 (en)	2022-05-24	2023-11-30	Daiichi Sankyo Company, Limited	Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024013723A1 (en)	2022-07-15	2024-01-18	Pheon Therapeutics Ltd	Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024023750A1 (en)	2022-07-28	2024-02-01	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
US20240101718A1 (en)	2022-09-28	2024-03-28	Incyte Corporation	Anti-pd-1/lag-3 bispecific antibodies and uses thereof
WO2024074498A1 (en)	2022-10-04	2024-04-11	Imcheck Therapeutics	Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2024116094A1 (en)	2022-11-30	2024-06-06	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugates and dnmt inhibitors
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (ja) *	1978-08-17	1985-08-02	富士電機株式会社	魚切断加工自動化装置
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6014678A (ja) *	1983-07-04	1985-01-25	Taiheiyo Kogyo Kk	電磁弁
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB2188941B (en) *	1986-04-14	1990-06-06	Bayer Ag	Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (da) *	1986-11-19	1988-07-18	Novo Industri As	Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer
GB8720833D0 (en) *	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
GB2216126B (en) *	1988-02-12	1992-06-03	Medical Res Council	Antibodies to the antigen campath-1
EP0362371A4 (en) *	1988-04-15	1990-10-24	Protein Design Labs, Inc.	Il-2 receptor-specific chimeric antibodies
JP5598363B2 (ja)	2011-02-15	2014-10-01	ソニー株式会社	記憶装置およびその動作方法

1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active IP Right Cessation
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en active IP Right Grant
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
1990
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 DK DK911191A patent/DK119191D0/da not_active Application Discontinuation
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
1992
- 1992-01-20 BG BG95784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
- 1998-12-28 HK HK98115967A patent/HK1014718A1/xx not_active IP Right Cessation
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
2000
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
2001
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
2003
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
2006
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active

Also Published As

Publication number	Publication date
NL990020I2 (nl)	1999-11-01
IL162181A (en)	2006-04-10
NO2001026I2 (no)	2006-11-20
ES2492815T1 (es)	2014-09-10
EP0451216B1 (en)	1996-01-24
DK119191A (da)	1991-06-19
IL162181A0 (en)	2005-11-20
DD296964A5 (de)	1991-12-19
EP1477497A1 (en)	2004-11-17
LU90528I2 (fr)	2000-04-11
HRP920500B1 (en)	1999-12-31
DK119191D0 (da)	1991-06-19
CA2328851C (en)	2002-08-13
NZ231984A (en)	1997-06-24
CA2328851A1 (en)	1990-06-28
CN1043875A (zh)	1990-07-18
ZA899956B (en)	1990-10-31
NO2009026I1 (no)	2009-11-30
NO912385L (no)	1991-06-19
JPH04502408A (ja)	1992-05-07
JP2003245091A (ja)	2003-09-02
EP0939127A2 (en)	1999-09-01
NO2005026I2 (no)	2009-01-19
NO2001025I2 (no)	2005-03-21
DE68929061D1 (de)	1999-09-30
LU90411I2 (fr)	1999-09-02
SG78258A1 (en)	2001-02-20
SI8912489A (sl)	1999-02-28
LU91333I2 (fr)	2007-06-11
BG61095B2 (en)	1996-10-31
NL300173I1 (nl)	2005-04-01
NL990020I1 (nl)	1999-09-01
PT92758B (pt)	1996-01-31
DE10075005I1 (de)	2000-11-23
EP1491556A1 (en)	2004-12-29
NO2007006I1 (no)	2007-05-07
DE10075005I2 (de)	2005-06-23
JP2828340B2 (ja)	1998-11-25
ES2523810T3 (es)	2015-01-12
NO2005005I2 (no)	2009-01-19
EP0451216A4 (en)	1992-01-02
PT92758A (pt)	1990-06-29
DE68929061T2 (de)	2000-04-27
FR14C0070I1 (fr)	2014-10-24
EP0939127A3 (en)	2004-07-21
DE122005000057I1 (de)	2009-04-09
ES2081974T3 (es)	1996-03-16
ES2492815T3 (es)	2014-10-08
NL300279I2 (nl)	2007-10-01
YU248989A (en)	1991-10-31
EP0451216B2 (en)	2012-06-13
DE98204240T1 (de)	2014-08-21
DE68925536T3 (de)	2012-11-22
NO2006009I1 (no)	2006-08-07
NL300213I1 (nl)	2006-02-01
NL300213I2 (nl)	2006-07-03
DE04076438T1 (de)	2014-02-27
ATE133452T1 (de)	1996-02-15
JP2003245090A (ja)	2003-09-02
NL300239I2 (nl)	2007-03-01
HU211174A9 (en)	1995-11-28
HRP920500A2 (en)	1996-04-30
NO310473B1 (no)	2001-07-09
NO2005026I1 (no)	2005-12-27
HK1014718A1 (en)	1999-09-30
IL92904A0 (en)	1990-09-17
NL300279I1 (nl)	2007-07-02
NL300005I1 (nl)	2000-04-03
DE122005000007I1 (de)	2005-06-30
KR910700350A (ko)	1991-03-14
KR0178385B1 (ko)	1999-04-01
DE122005000007I2 (de)	2009-06-25
ES2081974T5 (es)	2012-10-29
LU91272I2 (fr)	2006-10-09
DE10075038I2 (de)	2004-08-12
DE68925536T2 (de)	1996-06-20
JP3604058B2 (ja)	2004-12-22
NL300239I1 (nl)	2006-10-02
NL300005I2 (nl)	2000-10-02
NO2006009I2 (no)	2009-12-07
AU5153290A (en)	1990-08-13
EP0682040A1 (en)	1995-11-15
DK199800941A (da)	1998-07-16
ES2440825T1 (es)	2014-01-30
LU91208I2 (fr)	2006-02-28
AU647383B2 (en)	1994-03-24
NL300023I2 (nl)	2001-09-03
EP0939127B1 (en)	2014-09-17
ES2523810T1 (es)	2014-12-01
NL300426I1 (nl)	2010-02-01
MC2146A1 (fr)	1992-02-18
CA2006865C (en)	2002-08-20
FI912436A0 (fi)	1991-05-20
NL300173I2 (nl)	2006-05-01
EP2341080A1 (en)	2011-07-06
NL300023I1 (nl)	2001-01-02
EP1477497B1 (en)	2014-11-26
NO2001024I1 (no)	2002-01-21
DK174317B1 (da)	2002-12-02
LU90676I2 (fr)	2001-02-05
YU48700B (sh)	1999-07-28
DE122009000071I1 (de)	2010-03-25
JP2009165488A (ja)	2009-07-30
IE20000331A1 (en)	2001-02-21
ES2136760T3 (es)	1999-12-01
WO1990007861A1 (en)	1990-07-26
DE04076439T1 (de)	2014-12-18
ES2440825T3 (es)	2014-05-19
DE122005000057I2 (de)	2009-07-16
CN1057013C (zh)	2000-10-04
EP0451216A1 (en)	1991-10-16
DE19975047I2 (de)	2008-07-03
EP0451216B9 (en)	2012-09-26
DE10075038I1 (de)	2001-03-01
CZ418691A3 (en)	1993-10-13
DE68925536T4 (de)	1996-09-19
EP1491556B1 (en)	2014-04-30
JPH114694A (ja)	1999-01-12
EP0682040B1 (en)	1999-08-25
JP2007145863A (ja)	2007-06-14
DE68925536D1 (de)	1996-03-07
LU91139I2 (fr)	2005-04-04
RU2126046C1 (ru)	1999-02-10
SI8912489B (sl)	2000-04-30
ATE183753T1 (de)	1999-09-15
NZ314793A (en)	1999-11-29
NO2007006I2 (no)	2009-12-07
LU91627I2 (fr)	2010-02-09
NO912385D0 (no)	1991-06-19
CA2006865A1 (en)	1990-06-28
DE122006000036I1 (de)	2007-04-19
DE122007000037I1 (de)	2007-08-02

Legal Events

Date	Code	Title	Description
2002-11-29	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20020014
2005-02-25	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20050004
2005-12-16	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20050028
2006-08-07	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20060010
2006-11-07	PC	Transfer of assignment of patent	Owner name: PDL BIOPHARMA, INC. Free format text: PDL BIOPHARMA, INC.
2007-04-13	SPCF	Supplementary protection certificate application filed	Free format text: SPC L20070013 Spc suppl protection certif: L20070013
2007-10-16	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: L205 Extension date: 20140728
2008-03-05	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: L209 Extension date: 20130303 Spc suppl protection certif: L210 Extension date: 20140813
2008-05-15	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: NUMBER:215 Spc suppl protection certif: NUMBER:216
2008-10-31	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: NUMBER:228 Spc suppl protection certif: NUMBER:227
2009-11-19	SPCF	Supplementary protection certificate application filed	Free format text: SPC C20090039 Spc suppl protection certif: C20090039
2010-08-10	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: 282 Extension date: 20141228
2010-08-16	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: 282 Extension date: 20141228
2011-02-09	SPCL	Withdrawal, rejection or dismissal of a supplementary protection certificate	Spc suppl protection certif: C20090039 282

Publication	Publication Date	Title
FI108797B (fi)	2002-03-28	Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja
AU631545B2 (en)	1992-12-03	Il-2 receptor-specific chimeric antibodies
EP0781845B1 (en)	2003-04-02	Anti-human milk fat globule humanised antibodies and processes for their production
EP0566647B1 (en)	2003-10-08	Improved humanized immunoglobulins
EP0794966B1 (en)	2002-08-28	Humanized antibodies to cd38
WO1993001289A1 (en)	1993-01-21	Humanized interleukin-2 receptors antibodies